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Abstract

Although improvement in the detection and treatment of
hypertension has occurred over the last two decades,

the

trends have stagnated over the last 5 years with a related
increase in mortality from cardiac failure and an
increased incidence of end-stage renal disease.

Current

researchers have made a strong argument that many health
care providers have not been successfully managing
hypertension at a level,

as established by research,

to

prevent target organ disease over time. As health care
providers,

family nurse practitioners

nurse practitioners

(ANPs)

(FNPs)

and adult

are managing hypertension in

outpatient settings as primary care nurse practitioners
(PCNPs). This descriptive study sought to answer two
research questions:

How effectively are PCNPs

implementing the JNC VI guidelines for hypertension
management in practice? And are PCNPs aware of the current
national guidelines

(JNC VI)

for hypertension management?

Ten critical factors/interventions were measured to
evaluate compliance with the JNC VI guidelines and were
analyzed with descriptive statistics of frequency.

111

Data

analysis revealed that the PCNPs in the study were
n o n c o m p liant with the use of the JNC VI guidelines in
practice and encouraged recommendations in PCNP education
and practice for the future.

IV

Table of Contents

Page
A b s t r a c t ................................................

iii

List of T a b l e s .........................................

vii

Chapter
I.

The Research Problem ............................

1

Establishment of the Problem ..................
Significance to Nursing
.......................
Theoretical Framework
.........................
A s s u m p t i o n s ....................................
Statement of the P r o b l e m .......................
Research Questions ..............................
Definition of T e r m s ...........................

3
10
12
14
15
16
16

II.

Review of the L i t e r a t u r e .......................

18

III.

The M e t h o d .......................................

55

IV.

V.

Design of the S t u d y ...........................
Setting, Population, and Sample
..............
S e t t i n g .......................................
P o p u l a t i o n ..................................
S a m p l e .......................................
Instrumentation
................................
Methods of Data C o l l e c t i o n ....................
Data A n a l y s i s ..................................

55
56
56
56
57
57
64
66

The F i n d i n g s .....................................

69

Description of the S a m p l e ....................
Results of Data A n a l y s i s .......................

70
70

The O u t c o m e s .....................................

78

D i s c u s s i o n .......................................
L i m i t a t i o n s ....................................
Significance to Nursing
.......................

80
87
88

V

C o n c l u s i o n s ....................................
Recommendations
................................

89
90

R e f e r e n c e s ..............................................

92

Appendix
A.

Cag le 's JNC VI Guidelines Compliance
S u r v e y .......................................

96

Approval of Mississippi University for
Women's Committee on Use of Human
Subjects in Experimentation ................

101

C . Letters to P a r t i c i p a n t s ........................

103

B.

D.

E.

Second Consent Letter and Request
for P a r t i c i p a t i o n ...........................

105

JNC VI Awareness Questionnaire/Postcard

108

VI

.

. .

List of Figures

Table

Page

1.

Distribution of s c o r e s ..........................

71

2.

Clinical sites--hospital

72

3.

Clinical sites--private practice

4.

Clinical setting--all other settings

..........

73

5.

Case study # 1 ...................................

75

6.

Case study # 2 ...................................

75

7.

Case study # 3 ...................................

76

8.

Prescriptive compliance with JNC
g u i d e l i n e s .......................................

77

VI1

.......................
..............

73

Chapter I
The Research Problem

Cardiovascular disease has been cited by health care
professionals as the main health problem facing the United
States.

Heart disease has been established as the number

one cause of mortality in the United States with 724,859
deaths in 1998
1998).

(National Center for Health Statistics,

Over the last 30 years researchers have concluded

that hypertension is a strong predictor of future
cardiovascular disease and other target organ disease when
uncontrolled
Whelton,

(Belanger,

1999; Kennel,

Cupples,

& D'Agostino,

1988; He &

1999) . This recognition of

hypertension as a related cause of cardiovascular disease
and other target organ diseases has led many developed
nations to formulate national programs and guidelines for
hypertension control.
The United States' version of a national hypertension
control program was started in 1973 with the National
Heart,

Lung,

and Blood Institute

(NHLBI)

establishing the

National High Blood Pressure Education Program
1997).

(NHLBI,

The NHLBI formed a committee of professionals from
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various professional and governmental health care agencies
to meet needs of inadequate detection and treatment of
hypertension in the United States.
appointed,
Prediction,

The last committee

the Sixth Joint National Committee for the
Detection,

Blood Pressure

Evaluation,

and Treatment of High

(JNC VI), met and created the most recent

national guidelines for hypertension management in 1997.
Over the last 27 years,

health care providers implementing

NHLBI guidelines have reduced the mortality rates for
stroke and coronary heart disease significantly and
increased the awareness and treatment of hypertension
nationwide

(NHLBI,

1997).

Although multiple and various methods of research,
including controlled trials,

were used in formulating

these guidelines for hypertension management,

many health

care professionals are not complying with the guidelines
in practice as revealed by current literature and
statistics.

This perplexing problem has a direct effect on

the care provided to patients and motivated the current
study to ascertain how primary care nurse practitioners
(PCNPs)

are managing their health problem.

PCNPs treat and

manage medical illnesses using standardized guidelines for
practice in a medica/curing model.

PCNPs also practice

from a nursing/caring model that is influenced by nursing
experience and education prior to specialized education in

3

the PCNP role.

This researcher explored the role of PCNPs

as a separate population from physicians to determine how
they approached hypertension management,

especially in

regard to compliance with national hypertension
guidelines.

Establishment of the Problem
Hypertension management in the United States has been
a concern of almost all health care providers because of
the strong causal and predictive relationship to
cardiovascular disease,
renal disease,

peripheral vascular disease,

target organ disease
1999;

Kennel,

cerebrovascular disease,

1999;

(Belanger et al.,
Stamler,

Stamler,

end-stage

and other

1988; He & Whelton,
& Neaton,

1993).

Due

to this recognition of hypertension as a causative factor
for significant amount of mortality and morbidity
worldwide,

most developed countries have endorsed national

hypertension control programs.

In the United States,

the

NHLBI has appointed a joint national committee every 5
years since 1973 to study and update national guidelines
for health care professionals to use for hypertension
management.

The JNC VI revealed some alarming trends over

the last 5 years that suggest the need for improvement in
hypertension management strategies by health care
providers

(NHLBI,

1997).

The areas of greatest concern
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were an increase in the incidence of mortality from
cardiac failure,
renal disease

an upsurge in the incidence of end-stage

(ESRD), and a slight statistical rise in the

incidence of age-adjusted stroke rates

(NHLBI,

1997).

The

JNC VI determined that hypertension is "the second most
common antecedent" in ESRD and a "common antecedent" in
heart failure

(NHLBI,

1997, p. 5).

Cardiovascular disease and stroke are very costly in
health care dollars spent in the care for these diseases.
The JNC VI reported that cardiovascular disease costs
"impose an enormous financial burden on Americans

[with]

more than $259 billion in direct and indirect cost
[yearly]"

(NHLBI,

1997, p. 7). Current researchers believe

that part of this problem is related to failure to follow
established hypertension management guidelines and
personal clinical practice beliefs of health care
providers in current practice that are not established
through research
Swales,

(Dustan,

1998;

Perry et al.,

1998 ;

1999). Although the JNC VI has recommended that

health care providers control their patients'

blood

pressure at a level of < 140/90 mmHg to prevent target
organ disease and optimally < 120/80 mmHg,

current

researchers argue that this is not being done effectively
(Berlowitz et al.,
Swales,

1999).

1998;

Dustan,

1998;

Perry et al.,

1998;
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Health care providers are overlooking systolic
hypertension,

especially in the elderly,

due to beliefs

that it is too variable to be a predictor of
cardiovascular disease
1998 ; Swales,

1999).

in Hypertension:

(Berlowitz et al.,

One study.

1998;

Dustan,

Current Clinical Practice

The EISBERG project

(Swales,

1999),

exemplified the current inadequate hypertension control.
The EISBERG project made a strong argument that systolic
hypertension is not being controlled effectively in the
United States and in six other developed countries.

This

project used a quantitative analysis of data received from
seven countries,

1,486 general practitioners,

patients to discover some unsettling findings.

and 17,359
Only 49% of

patients in the study were controlled at a blood pressure
< 160/90 mmHg and only 30% to the level of < 140/90 mmHg
as established by the JNC VI and other countries'
hypertension guidelines.

This example of ineffective

systolic hypertension was consistent with the statement by
the JNC VI,

"nearly three-fourths of adult Americans with

hypertension are not controlling their blood pressure to
below 140/90 mmHg"

(NHLBI,

1997, p. 8). Similarly,

statistics reported by the Third National Health and
Nutritional Survey show that "69% of hypertensive subjects
were aware of

[their]

elevated blood pressure,

53% were
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receiving treatment,
1999,

and 24% were controlled"

(Swales,

p. 232).
The EISBERG project results also imply that systolic

blood pressures have not been as rigidly controlled as
diastolic blood pressures.

The authors reported that more

than 50% of the sample patients had a diastolic blood
pressure controlled to a level endorsed by their country's
national guidelines,

but less than 40% of the patients had

a systolic blood pressure controlled at this level.
(1999)

Swales

concluded that part of this mismanagement of

systolic blood pressure was due to some physicians having
"a skeptical

[belief]

blood pressure

...

about the significance of systolic
it was too variable to be a reliable

predictor of cardiovascular risk

[and] diastolic blood

pressure is more readily controlled"

(p. 234).

This

opinion was generated following the analysis of the
qualitative data on hypertension management beliefs
received during the study which included opinions of 30
general practitioners.
Other results in the EISBERG project implied that a
patient's age affected hypertension control.

For example,

the general practitioners who were interviewed treated
patients older than 65 years less aggressively,

as the

majority did not institute pharmacological treatment until
blood pressure was 170/100 mmHg

(Swales,

1999).

The
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EISBERG project,
NHLBI

along with an advisory statement from the

(Izzo, Levy,

& Black,

2000),

highlighted a belief by

some physicians that an elderly person's age plus 100 mmHg
was an appropriate blood pressure.

These beliefs and

treatment practices are not congruent with the JNC VI
guidelines or recent research findings which stated that
systolic hypertension is a strong predictor of
cardiovascular disease and should not be overlooked as a
natural part of aging as blood vessels lose their
elasticity
Kennel,
1993).

(Belanger et al.,

1999;

1988; He & Whelton,

Staessen et al.,

2000;

1999;

Stamler et al.,

Izzo and his colleagues reviewed results from the

Lloyd-Jones

(1999)

study which used data from the

Framington Heart Study cohort to measure systolic
hypertension's ability to predict need for pharmacologic
treatment.

Izzo et al. stated that "systolic blood

pressure alone correctly classified blood pressure stage
in 91 percent of individuals who were potential candidates
for antihypertensive therapy compared to 22 percent who
were correctly classified using diastolic blood pressure
values"

(Izzo et al.,

2000, p. 2).

Uncontrolled systolic hypertension is a strong
predictor of a stroke and is a prevalent cause of
m or tality nationwide
Staessen et al.,

(He & Whelton,

1999; Kennel,

2000; Stamler et al.,

1993).

1999;

The National
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Center of Health Statistics

(NCHS)

report that stroke is

the third cause of death in the United States.
Mississippi,

the main setting for this study,

However,
has an 18%

higher stroke rate than the national average as reported
by the American Heart Association

(Penman & Johnson,

2000). Another alarming statistic for the state of
Mississippi concerning mortality related to strokes was
that one fourth of the stroke-related deaths were in
patients less than 65 years of age
2000).

(Penman & Johnson,

The detection and treatment of hypertension have

been a problem in Mississippi.

Approximately one third of

the state's population has hypertension,

and one third of

those citizens with hypertension have not been diagnosed
(Penman & Johnson,

2000).

Of those diagnosed,

"half are

not on treatment,

for one reason or another"

Johnson,

9). The problems with detection of

2000,

p.

(Penman &

hypertension may be attributed to a lack of access to a
provider in many outlying rural areas in Mississippi.
Family nurse practitioners
practitioners

(ANPs)

(FNPs)

and adult nurse

are primary care providers that work

in rural areas to meet the health needs of these
underserved populations.

These PCNPs are educated to

detect and treat hypertension as part of their advanced
practice role.

PCNPs use scientifically supported medical

research to guide their practice.

PCNPs also are educated

to use guidelines for practice with various disease
processes.

PCNPs in this respect follow a medical/curing

model when approaching patient care.
On the other hand,

PCNPs are registered nurses who

have received education as advanced practice nurses to
approach patients from a nursing/caring model.

This is

important as the nursing/caring model stresses the
importance of health teaching and promotion with close
contact with the patient. Although recent research has
sought to determine the degree of satisfaction related to
performance of care between physicians and nurse
practitioners

(NPs) by patients,

no research was found

that studied PCNPs as a separate population in regard to
their compliance with medical guidelines in practice.

This

current researcher sought to add to the scientific
foundation of nursing by evaluating PCNPs' ability to use
the JNC VI guidelines in practice.

Implementation of this

descriptive research was important to evaluate the care
for patients with hypertension across the adult life span.
Analysis of the research data can be used to formulate
future educational and practice evaluation guidelines for
PCNPs.
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Significance to Nursing
Although improvements concerning nurse practitioner
professional practice issues have been addressed through
state and national legislation,

some physicians are still

fighting NPs at every turn regarding their professional
scope of practice.

A recent legislative update concerning

NP practice issues stated,

"The AMA has an intensive

online advocacy campaign to help medical societies defeat
state and national legislation that improves practice
authority of APN and other providers

...

as part of the

AMA's plan to sustain physician control over other
providers"

(Pearson,

2001, p. 14). The AMA,

according to

the author of the update,
. . . submitted a "Citizens Petition" to the
HCFA in July 2000 [which] . . . insists that NPs
and CNSs should be forced to work in
collaboration with physicians, [that] HCFA has
failed to uphold the intent of Congress and its
duty to taxpayers and medical beneficiaries by
encouraging APNs to practice beyond legally
authorized safeguards. (Pearson, 2001, p. 14)
Although recent studies have supported the NP's
ability to competently care for patients while being
economically conscientious,

NPs still face many

professional practice issues,
reimbursement,

such as

(a) direct

(b) prescriptive authority restrictions,

(c) hospital privilege restrictions,

and

of practice concerning medical procedures

(d) limited scope
(Pearson,

2001).
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One main issue affecting many NPs is legislation
controlling prescriptive authority.
majority of states

(N = 38)

Currently,

the

in the United States require

NPs to have physician's involvement,

with prescriptions

written with their name on the prescription pad or
delegation by physicians concerning medications that can
be prescribed in practice

(Pearson,

2001). Although many

studies have been performed concerning N P s ' ability to
care for patients in various medical settings with diverse
medical populations,

some controversy remains regarding

NPs receiving enough pharmacological education to be
competent in prescriptive practice. A review of the
literature concerning NPs' prescriptive competence yielded
no results on different pharmacologic classes of
medication.

Further outcome research concerning competent

prescriptive practice of various pharmacologic classes of
medication is needed to push future legislation to respect
the NP's ability to competently prescribe all classes of
medication without physician supervision or delegation.
This research aims to add scientifically relevant data to
help fill this gap in outcome-based,

nurse practitioner,

prescriptive practices by focusing on how NPs follow
national guidelines in treating hypertension

(HTN) with

antihypertensive medications along with other
nonpharmacologic measures.

Results from studies on NP
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prescription practice along with future outcome oriented
research concerning NP treatment methods should allay
fears by the health care consumer,

give confidence to

legislators involved in NP professional practice issues,
and subdue doubt and argumentation of the aforementioned
health care p r o v i d e r s .

Theoretical Framework
Imogene King's Theory of Goal Attainment was the
theoretical framework used to guide the study.
Theory of Goal Attainment,

a dyad,

In King's

or group of two people,

come together to form an interpersonal system.

This

interpersonal system relies on communication to provide
interaction between the two people in the dyad
1981).

(King,

The PCNP and the patient with hypertension

exemplify the dyad in this study.

King explained in her

theory that interaction allows the nurse to develop a
model of transaction/interaction that shares theoretical
knowledge used by nurses to help individuals and groups
achieve their goals

(King,

1981). Mutual goals toward

health are formed and agreed upon by the nurse and patient
and include the following steps:
of a client's concerns,
health;

(b)

problems,

"(a)

nurses'

assessment

and disturbances in

[the] nurse's and client's perception of the

interference;

[and]

(c) their sharing of information
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whereby each functions to help the client attain the goals
identified"

(King,

1995, p. 28).

Transaction is explained as a process in which both
the nurse and the client perform actions together to meet
a goal they have agreed upon.
nurse,

This process depends on the

or in the current study,

the PCNP,

appropriate information to clients"
1998,

p. 306)

to occur.

to "communicate

(Tomey & Alligood,

to allow mutual goal setting and attainment

The PCNP must be knowledgeable about current

modalities of treatment and management of disease process
to be effective in this process.

Hypertension management

can be controlled by both lifestyle modification and
pharmacological treatment.
most current,

The PCNP should be aware of the

effective treatment interventions in regard

to hypertension management to efficiently formulate
competent treatment regimens for hypertensive patients.
There also is a need for mutual goal setting between
the PCNP and the patient in this process to ensure patient
compliance with a treatment regimen. Antihypertensive
medications have various side effects that are worrisome
to patients and cause these patients to alter the
prescribed antihypertension medication regimen.

Some

hypertensive patients are not aware of arteriosclerosis
and hyperlipidemia,

along with other lifestyle factors as

scientific evidence of hypertension.

PCNPs should
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constantly interact with these patients and determine
their perception of treatment interventions in an effort
to formulate goals toward hypertension management and
ensure compliance.

King states in her theory,

"if

perceptual accuracy is present in nurse-client
interactions,

transactions will occur,

client make transactions,
Alligood,

[and]

if nurse and

goals will be obtained"

(Tomey &

1998, p. 306).

Assumptions
The following assumptions were made in formulating
the design and are regarded as principles that are
believed to be true and relevant to the current research:
1. PCNPs value established research on medical and
nursing treatments as the foundation for competent
practice.
2. The JNC VI guidelines for hypertension management
are valid for the management of hypertension and are
adequately backed by scientific research.
3. PCNPs have the proper education and clinical
preparation to effectively predict,

detect,

evaluate,

treat hypertension.
4. PCNPs can be effective in the management of
disease process in patients through use of mutual goal

and
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setting by sharing specialized knowledge contained in
guidelines for medical practice.

Statement of the Problem
Hypertension detection and treatment have improved
over the last two decades,

but the trends have stagnated

over the last 5 years with an increase in the incidence of
mortality from cardiac failure and an increased incidence
of end-stage renal disease

(NHLBI,

1997).

This dilemma is

largely due to mismanagement of systolic blood pressure at
parameters > 140 mmHg despite valid research that systolic
blood pressure is a strong predictor of future
cardiovascular and renal disease. Many health care
providers still hold beliefs that systolic blood pressure
is too variable to be an adequate predictor of future
cardiovascular disease

(CVD). These health beliefs are not

supported by scientific research and are inconsistent with
national guidelines that support a blood pressure
measurement of < 140/90 mmHg,

especially in elder clients

to prevent further target organ disease

(NHLBI,

1997).

PCNPs may not be managing high blood pressure by
using national guidelines despite adequate research which
asserts that high blood pressure maintained at a level >
140/90 mmHg puts patients at risk for target organ
disease.

This researcher explored how compliant PCNPs were
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in using the scientifically backed JNC VI recommendations
for hypertension management.

Research Questions
For this study,

the following research questions were

formulated :
1. How effectively are PCNPs implementing the JNC VI
guidelines for hypertension management in practice?
2. Are PCNPs aware of the current national guidelines
(JNC VI)

for hypertension management?

Definition of Terms
The following concepts,

essential to the study,

were

defined to help the reader better comprehend their
meaning.

The theoretical definition is the definition of

the concept as it relates to the literature reviewed for
the study.

The conceptual definition is the operational

definition or how the concept is used in the study.
Primary care nurse practitioner
a licensed,

certified,

(PCNP): T h e o r e t i c a l :

advanced practice nurse,

who acts

as a primary care provider and provides medical care to
patients of various ages within a family.

Conceptual:

family nurse practitioner or adult nurse practitioner,
certified and licensed in the state of Mississippi,
performing the role of a primary care provider,

who has at
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least 1 year of experience and practices in Mississippi,
Alabama,

Tennessee,

or Louisiana.

Hypertension management:

Th eo re ti ca l: maintenance of

a blood pressure measurement within the prescribed JNC VI
parameter to prevent the onset,

or progression,

of target

organ disease in a patient medically diagnosed with or in
treatment for hypertension.

Co nc ep t ua l: the maintenance of

a blood pressure measurement < 140/90 mmHg without organ
disease and a blood pressure measurement of < 130/80 mmHg
with target organ disease in a patient,
age,

35 to 55 years of

to prevent onset or progression of target organ

disease.
JNC VI guidelines.

Theor et ic al : " . . .

national

guidelines formulated by the National High Blood Pressure
Education Program of the National Heart,

and Blood

Institute to predict,

detect,

hypertension"

1997, p. 5). C o n c e p t u a l : national

(NHLBI,

evaluate,

Lung,

and treat

guidelines formulated by the National High Blood Pressure
Education Program of the National Heart,
Institute to predict,
hypertension.

PCNPs'

detect,

evaluate,

compliance with,

Lung,

and Blood

and treat

and awareness of,

the national hypertension management guidelines

(JNC VI)

were measured using 10 critical factors identified on
Cagle's JNC VI Guidelines Compliance Survey.

Chapter II
Review of the Literature
A review of the literature was performed to validate
and establish a need for this study on PCNPs and
hypertension guidelines compliance.
was found to support the concepts,

Very limited research
and only one set of

researchers discussed nurse practitioners

(NPs)

in

hypertension management using national hypertension
guidelines.

The limited amount of research found was in

itself an indication of the need for research,

and the

literature found did make a sound argument for this study
and is made evident by findings reviewed in the studies
that follow.
Goldberg et al.

(1998)

directed their research to

evaluate how effective continuous quality improvement
(CQI)

teams and academic detailing

(AD) were in producing

change in clinical practice concerning hypertension
and depression.
authors was,

(HTN)

The research problem as identified by the

although clinical guidelines for practice

have been developed and disseminated over the last two
decades,

compliance by health care providers has been very

18
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minimal

(Goldberg et al.,

1998). AD and CQI have been

successful methods for altering practice in medication
prescription practice and industrial management,

but have

not been studied in regard to chronic disease and
treatment

(Goldberg et al.,

1998). Thus,

the researchers

listed three research questions:
1. How well were the AD techniques and CQI team
interventions implemented within clinics?
2. How effective were both interventions in
increasing compliance with guideline recommendations
across clinics?
3. If variation in implementation was observed,

were

instructive associations between implementation success
and outcome improvement demonstrated?
Academic detailing was defined as "one-on-one
education and feedback sessions"
p.

130)

(Goldberg et al.,

1998,

provided by experts concerning guidelines for

clinical management of HTN and depression,

and CQI teams

as "a model in which entire organizations commit to
reducing unwanted practice variation at all levels"
(Goldberg et al.,

1998, p.

131).

Blood pressure control

was defined as a blood pressure measurement < 160/90 mmHg,
and a diastolic blood pressure measurement < 80 mmHg was
described as over-controlled

(Goldberg et al.,

1998).

20

The study design used was a descriptive,

pretest-

posttest experimental design which gathered baseline data
for 12 months,
AD,

CQI,

followed by 6 months of intervention with

or both,

and then re-gathered data for 12 months

post-interventions.
Washington,

Four clinical sites in the Seattle,

area provided the settings.

were HMO affiliated,

Two of the clinics

one was a university-based hospital

and the last site was a veterans clinic.
A blocked and randomized sampling design was utilized
and consisted of 15 small groups of health care
practitioners including 95 health care providers and 4,955
patients in total.

The patients were by majority Caucasian

(> 84%)

and male

{> 7 4%)

represented were internal medicine practitioners

as a speciality.

(> 51.4%).

The majority of physicians

The patients used in the HTN portion of

the study were "known hypertensives" and described as
"patient with a mean blood pressure value > 160/90"
(Goldberg et al.,

1998, p. 133).

Differences between

samples were compared through the use of analysis of
variance and contingency table analysis,

as data were

received from seIf-administered questionnaires and surveys
(Goldberg et al.,

1998).

There was a control group for the

study which received usual care
compare the results.

(UC) during the study to
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The AD intervention was performed

by two physicians

at each site giving 15-minute lectures
guidelines for hypertension,

on information from

followed by two follow-up

sessions conducted by pharmacists concerning prescription
patterns.
The CQI teams were implemented by CQI facilitators
for the first couple of months of the study and then
supervised by physician team leaders.

The CQI facilitator

trained physician team leaders in "team based approaches
. . . to improve quality" and informed team on change
process by facilitating the "Shewart cycle of activities
. ,. [to] plan,
132).

do,

study,

act"

(Goldberg

et al.,

1998, p.

Each team collected its own data at its own pace and

was free to choose interventions to change processes as
problems presented themselves during the data collection.
The only limitation was that interventions had to be
geared toward the five recommendations formulated for HTN
and depression.
The recommendations related to hypertension were

(a)

the prescribing of beta-blockers and potassium-sparing
diuretics specifically promoted,

(b) the prescribing of

calcium channel blockers and ACE inhibitors were "to be
reserved for special indications or when first-line drugs
have proven ineffective," and

(c) blood pressure control

to be performed without placing patients at risk for
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"over-control"

(Goldberg et al.,

1998, p. 132).

There were

three to five groups at each site participating in the
study receiving either AD,

CQI, both,

or UC. The

instruments for data collection were varied from
information systems in pharmacy to collect prescription
patterns to written charts in the hypertension portion of
the study.
Data were analyzed using mean percentages for all
clinics and highest percentage change as "best case
clinic" to reflect changes following interventions and
compared to usual care

(UC). Differences between samples

were compared through the use of analysis of variance and
contingency table analysis,

as data was received from

self-administered questionnaires and surveys.

Pairwise t

tests were used to distinguish changes of one intervention
in comparison with the others and usual care.
were designed to give a good degree of power
revealing a 10% change as HTN control

The samples
(80%)

in

(Goldberg et al.,

1998).
There were only two significant findings
In the county,

(p < .05).

Harborview Medical Center, AD + CQI were

statistically significant

(p = .01)

in producing an

increased change in the prescription of diuretics as
compared to UC. The other significant finding

(p = .00)

was in regard to AD + CQI teams versus AD in increasing
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the percentage of diuretic prescription in the same
setting.

There was less than a 3.8% mean increase in

prescription patterns of diuretics,
regimens,
CQI,

potassium-sparing

and beta-blockers in groups where AD,

interventions were implemented.

or AD and

Ironically there was

a higher percentage change in usual care patterns,
the highest percentage improvement

(+6.3% mean)

clinics in potassium-sparing regimens.

in AD + CQI groups versus usual care

(Goldberg et al.,

(+3.7%

(+3.1% mean)

1998). The decrease percentage in the

prescription of calcium channel blockers
ACE inhibitors

for all

There was only

slight improvement in beta-blocker prescribing
mean)

(+1.3% mean)

(-1.3% mean)

and ACE inhibitors

and

was also very poor as compared

to usual care changes for calcium channel blocks
mean)

with

(+2.1% mean).

(-4.6%

The analysis of

blood pressure control improvement means were also dismal,
with only an 8.2% increase in control for AD groups and a
3.9% increase in AD + CQI groups compared to a 9.6%
improvement in the usual care group. There was an increase
in over control of blood pressure,
study,

as defined by the

in all groups with a 3.1% increase in AD groups,

7.8% increase in the AD + CQI groups,
in the UC group

(Goldberg et al.,

The researchers concluded,
CQI team interventions

a

and a 10.6% increase

1998).

"neither the AD nor the

. . . were associated with
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improvement in prescribing patterns or control rates in
regard to guideline recommendations across clinics"
(Goldberg et al.,

1998, p. 132). This conclusion

illustrates that although reliable scientific research has
been established to improve treatment clinical
practitioners have failed to alter their management.
Although AD and the CQI techniques were performed
adequately in the setting there was a high degree of
freedom given to each setting concerning choices for
"process change and in identifying process deficiencies"
(Goldberg et al.,

1998, p.

132).

Due to this freedom,

it

is possible that the AD and CQI methods may have been
performed differently in these settings and had an effect
on findings,

but the homogeneity of results being

nonsignificant suggests that this was not the case.
The authors concluded that implementation of the AD
or CQI modalities was unlikely to produce any change in
compliance with established national guidelines for
practice and that CQI teams "may benefit from focusing
more on implementing process changes with
established effectiveness"
141). NPs,

. . .

(Goldberg et al.,

although a minority in number,

1998,

p.

were included in

the study with no stratification given as far as their
number in the composition of the veterans clinic portion
of the sample.
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NPs depend on medical models for practice and the
physician as a professional resource.

NPs need to be able

to distinguish practice that is scientifically sound as
compared to traditional or personal preferences in
practice.

Research is needed to evaluate NPs' management

of HTN in their clients and their knowledge of national
guidelines.
Another study,

Siegel and Lopez

(1997),

investigated

physician prescription patterns of antihypertension
medications 3 years after the initiation of the Fifth
Joint National Committee on Detection,
Treatment of High Blood Pressure
question was as follows:

Evaluation,

and

(JNC V ) . The research

Do the JNC V recommendations

affect prescribing? The JNC V recommendations that
received significant focus were hydrochlorothiazide

(HCTZ)

and beta-blockers as first-line antihypertensives in the
treatment of hypertension due to their results in reducing
"cardiovascular mortality and morbidity
controlled clinical trials"
1745).

...

(Siegel & Lopez,

in long-term
1997, p.

The researchers recognized that use of this

treatment was based on the absence of contraindications or
unacceptable circumstances for prescription
Lopez,

(Siegel &

1997). The variables under examination in this

study were prescriptions written for hypertensive patients
over a 3-year span. There were 200 medications that were
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determined to be the most frequently prescribed and were
calculated by information collected by Scott-Levin through
surveys to retail pharmaceutical companies
Lopez,

1997).

(Siegel &

The conceptual framework focused on the JNC

V guidelines and the impression that some physicians are
in disagreement with these guidelines.
Siegel and Lopez

(1997)

used a prospective,

descriptive design that selected retail pharmacies as the
population for the study.
as any of the following:

Retail pharmacies were defined
chain pharmacies

(27%),

independent pharmacies

(18%), pharmacy in mass merchandise

stores

(4%)

(8%),

and other

(Siegel & Lopez,

1997). The

retail market defined above was stated to "disperse
approximately 68% of all pharmaceuticals and diagnostics
in the United States"

(Siegel & Lopez,

1997, p.

1746).

The

35,000 retail pharmacies included in the study were drawn
randomly from all 50 states in the United States.

The

population of retail pharmacies from which the sample was
chosen was divided into 1,300 zones before being randomly
selected. After being chosen,

the retail pharmacies in

each zone were evaluated for homogeneity in regard to
prescription patterns using analysis of variance. Any
zones with a large degree of variance in prescribing
patterns were redefined to ensure homogeneity
Lopez,

1997).

(Siegel &
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The frequency of a medication being prescribed was
determined using data collection from the retail
pharmacies during the 3-year study. National figures for
prescriptions given from the pharmacies in the study were
calculated by multiplying the number of prescriptions in
one zone by a "zone area projection factor." This factor
was determined by "dividing the total number of
prescriptions dispensed for all

[medications]

retail pharmacies in the zone by the number of

by all
[one

specific medication prescribed in that zone by all retail
ph ar ma ci es ]" (Siegel & Lopez,

1997, p.

1746).

Thus,

data collected from all pharmacies in the study,

the

which

represented an estimate of 70% of all prescriptions in the
United States for retail pharmacies,

were projected to

estimate all prescriptions prescribed by retail pharmacies
in the United States.
During the analysis of data,

the prescriptions were

gathered into antihypertensive classes for the years 1992
and 1995,

and the estimated mean for frequency of

prescription was calculated from the total projected
number of medications prescribed nationwide in retail
pharmacies.

The estimated total wholesale cost of each

drug class prescribed was also calculated.

The cost

analysis was performed using "the average wholesale price
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as published in

the 1995 Drug

Lopez,

1746).

1997, p.

Topic Handbook"

(Siegel &

The researchers reported an increase in the
prescribing of calcium antagonist and ACE inhibitors and a
reduction of diuretics and beta-blockers from 1992 to
1995.

In the year 1992,

33% of antihypertensives

prescribed were

calcium antagonists and increased by 5% in

1995 to 38%.

the year 1992,25% of the prescriptions

In

were ACE inhibitors and increased 8% in 1995 to 33%.

Beta-

blocker prescriptions fell in number from 18% of all
antihypertensive prescribed in 1992 to 11% in 1995,

and

diuretic prescriptions were cut in half with a drop from
16% in 1992 to only 8% in 1995

(Siegel & Lopez,

1997).

There was also a tremendous cost associated with the
prescription of calcium antagonist and ACE inhibitors when
compared to the cost of diuretics and b e t a - b l o c k e r s . The
following cost analysis of calcium antagonist and ACE
inhibitor and diuretics and beta-blockers was contained in
the study:
The estimated US wholesale cost to retail
pharmacies for calcium antagonists was $2.67
billion in 1992 and $2.86 billion in 1995. Costs
for ACE inhibitors increased from approximately
$1.37 billion to $1.67 billion. Costs for the
diuretics decreased from $353 million to $168
million, while costs for the beta-blockers
decreased from $763 million to $433 million
during the same time period. (Siegel & Lopez,
1997, p. 1747)
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If diuretics had been 38% of the prescribed
antihypertensives for 1995, based upon previous figures,
their cost would have been less than $1 billion as
compared to the cost of the calcium antagonist
billion)

and ACE inhibitors

($1.67 billion).

beta-blockers also are cheaper in cost.

($2.86

Similarly

Beta-blockers had

an 11% prescription rate as compared to other
antihypertensives and an estimated cost of $433 million in
1995.

If the beta-blocker prescription rate had been 33%,

or three times what it was in 1995,
cost,

based upon figures above,

approximately $1.2 billion.
this opinion by asserting,

then the associated

would have been

Siegel and Lopez supported
"In 1995, based upon the

estimates herein the cost of each 1% of the national use
of the calcium antagonist was $75 million,
of each 1% of diuretic use was $21 million"
Lopez,

1997, p.

while the cost
(Siegel &

1748).

The results of this study provided evidence that
national guidelines concerning hypertension management do
not affect prescription practices by health care providers
despite long-term controlled trials that support its
prescription practice recommendations.

There were no

recommendations concerning the noncompliance implied by
the analysis of the data, but it is not difficult to
understand that the implications of noncompliance are
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costly.

Siegel and Lopez do give some possible causes for

the noncompliance to the JNC V guidelines including
Reduced results of diuretics and beta-blockers
in reducing coronary artery disease,
individualization of treatment based upon other
conditions, lack of dissemination of JNC V
recommendations, the attractiveness of using new
therapies, and the sale tactics of
pharmaceutical companies for the newer
antihypertensives, (p. 1748)
Further study with health care personnel in primary care,
such as family nurse practitioners

(FNP),

is needed to

evaluate if noncompliance with national guidelines
concerning prescription practice is prevalent in specific
settings with specific health care practitioners.
Perry et al.

(1998) provided supportive data that

validated the competency of the JNC VI guidelines in
regard to antihypertensive medication prescribing.

This

study also looked at hypertensive patients whose
hypertension was managed by "nurses and physician
assistants intensively trained in hypertension management"
(Perry et al.,

1998, p. 771)

as primary care providers.

Thee primary care providers used national hypertension
treatment guidelines written by the National High Blood
Pressure Education Program
Commission of Detection,
Blood Pressure

(JNC)

(NHBPEP)

Evaluation,

in treatment

and Joint National
and Treatment of High

(Perry et al.,

1998).
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The authors were concerned with examining 12
different antihypertensive medication regimens chosen for
treatment at Veterans Administration

(VA) clinics and

their efficacy in controlling hypertension.

The variables

examined were anti-hypertensive medication regimens as the
independent variable and hypertension measurement as the
dependent variable.

There were two research questions to

be answered by this study:
1. Which antihypertensive drugs were selected by the
involved health care providers?
2. How effective

[the antihypertensive drugs]

were in

achieving normotension?
The study was part of a Hypertension Screening and
Treatment Program

(HSTP)

established by the Department of

Veterans Affairs to provide hypertension treatment to
veterans and was performed over 46 months from May 1989 to
February 1993.

The authors described normotension as a

diastolic blood pressure measurement goal of 99 mmHg.
Hypertension measurements were determined by an average of
three readings "in minimally stressful conditions,
standardized mercury sphygmomanometers"
1998,

p. 722).

with

(Perry et al.,

The 12 antihypertension medication regimens

were defined as
(a) ND, no antihypertensive therapy, (b) D,
diuretic, (c) B, beta-blocker, (d) A, ACE
inhibitors, (e) C, calcium antagonist, (f) OD,
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other single antihypertensive drug, (g) D + B,
diuretic plus beta-blocker, (h) D + S, diuretic
+ non-beta blocker symptholytic agent, (i) D +
A, diuretic + ACE inhibitor, (j) D + C, diuretic
+ calcium antagonist, (k) D + OD, diuretic +
single antihypertensive agent not listed above,
and (1) o t h e r . (Perry et al., 1998, p. 772)
A descriptive correlational design was used in this
study and was interested in looking at the frequency of 12
different antihypertensive drug regimens prescribed by the
health care providers in the study and the medication
regimens efficacy in controlling hypertension by
correlating each regimen's outcome to the outcome of other
regimens in the study.

The researchers imposed no control

over the independent variable of antihypertensive
medication regimens in this study. The population for the
study was hypertensive veterans using VA clinics for
treatment of their hypertension. A convenience sample of
6,100 veterans who visited one of six HSTP clinics were
chosen for the study. The cohort studied was mainly male
(> 98%),

older than 60 years of age

regard to Caucasian race

(> 55%)

and equal in

(50%) and minority race

(50%).

The patients were observed and followed for hypertension
data for an average of 6.4 + 5.7 years and had a mean
blood pressure of 148/92 mmHg upon entering the HSTP.

The

settings for the study were six HSTP clinics in a wide
variety of geographical areas including the following :
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Indianapolis,
Iowa City,

IN; Jackson,

MS; Memphis,

10; and San Juan,

TN; St. Louis, MO;

Puerto Rico.

Data were collected from the sample
two forms.

(N = 6,100)

using

The first form gathered demographic and pre-

HSTP data including age,
family histories,
(Perry et al.,

race,

sex, height,

years of education,

past and

and marital status

1998). The second form was used in two

areas of data collection.

First,

it was used at each

clinic visit to gather a self-reported compliance with
antihypertensive drug regimen,
pressure readings,

an average of three blood

symptoms of treatment and severity,

medical history changes during time of study,
medications,

and weight.

evaluate alcohol intake,

Second,

it was used yearly to

tobacco use,

any abnormal

physical signs observed during treatment,
target organ disease,
al.,

1998).

other

and incidence of

and to document lab data

(Perry et

Data were collected and analyzed over a 46-

month period from 41,498 clinic visits.
The most frequently used antihypertensives were
diuretics

(54%) with the majority of these diuretics being

hydrochlorothiazide

(55%). The next most frequently used

antihypertensive drug regimens were calcium antagonists
(33%). Analysis of systolic blood pressure and diastolic
blood pressure in relationship to the medication regimens
was performed.

Diuretics and beta-blockers used in
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combination provide the lowest average systolic blood
pressure

(140.1 mmHg)

(149.0 mmHg)

and calcium antagonist the highest

(Perry et al.,

1998).

Diuretics also provided

the lowest average diastolic blood pressure results
mmHg)

(81.9

in the study and calcium antagonist the highest

average

(86.5 m m H g ) . Out of the six clinics,

the three

that used diuretics more than newer anti-hypertensive
agents of ACE inhibitors and calcium antagonists had an
average 6.2 mmHg lower systolic blood pressure in patients
(141.8/147.0)
pressure

and a 5.7 mmHg lower average diastolic blood

(82.0/87.7)

(Perry et al.,

1998).

The researchers

used a two-factor ANOVA to analyze differences between all
regimens.

The difference of results in regimens analyzed

in the seven most common regimens were considered
significant

(p < .0001)

and included the following drug

classes in the regimens either alone or in combination :
(a) diuretic,

(b) beta-blocker,

calcium antagonists.

(c) ACE inhibitor,

Of all the regimens used,

and

(d)

patients

who were on diuretics needed the least amount of change in
medication therapy

(4 6% not needing change)

as compared to

patients on ACE inhibitors or calcium antagonist

(18% not

needing c h a n g e ) .
The authors concluded that "for the elderly cohort
and the clinical condition described here,

the diuretic

was a more potent antihypertensive agent than was the
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calcium antagonist"

(Perry et al.,

1998, p.

1 1 1 ). Also,

diuretics and beta-blockers were associated with both
lower average blood pressures
diastolic)

(both systolic and

and lower percentage of lower uncontrollable

blood pressures

(14.9%/28%)

than calcium antagonists.

The

health care providers were noncompliant with JNC V
guidelines to control systolic blood pressure < 140 mmHg,
and 5% had a treated systolic blood pressure > 180 mmHg.
This noncompliance may be partially due to no set goal for
systolic blood pressure in the study, but the health care
professionals were aware of national guidelines for
treatment of systolic blood pressure as stated by the
researcher in regard to the health care professionals
using National High Blood Pressure Education Program and
JNC guidelines in treatment.

This study provides data that

nurses and physician assistants,

when competently using

national hypertension treatment guidelines,

can

effectively control hypertension to goal levels agreed
upon n o r m o t e n s i v e . The study, however,
that,

does show evidence

despite the use of national treatment guidelines for

hypertension,

these health care professionals were not

compliant in controlling systolic hypertension to a level
established by the JNC guidelines.

Further research must

be done to isolate NPs as a population in treating
hypertension to see if they are aware of hypertension
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guidelines,

implement these guidelines in practice,

and

whether their implementation of these guidelines is
effective in controlling hypertension.
One study in which the results support the JNC VI
guidelines used systematic review and meta-analysis of
first-line antihypertensive medications for success in
hypertension control

(Psaty et al.,

1997).

The purpose of

the study was to examine the efficacy of the four most
common antihypertensive medication classes in preventing
the occurrence of myocardial infarction and stroke through
the control of hypertension.
Eighteen randomized clinical trials were found for
analysis in the study by using MEDLINE and previous m e t a 
analysis

(Psaty et al.,

1997). The patients

(N = 48,220)

included in these studies were from the United States,
Europe,

Scandinavia, Australia,

and Japan.

The patients were followed for an average of 5 years
in the studies.
elderly,

The patients were all middle-aged to

and a few of the patients in various studies had

"very high blood pressure or . . . survived a stroke"
(Psaty et al.,

1997, p. 740). The randomized trials were

limited to trials which were "at least 1 year long,
placebo controlled,

and unconfounded by other therapies

. . . we excluded multiple risk factor intervention trials
and trials using first-line agents other than

[diuretics.
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B-blockers,

calcium channel blockers,

(Psaty et al.,

1997, p. 740).

and ACE inhibitors]"

The authors stated no trials

that evaluated calcium channel blockers and ACE inhibitors
were found in regard to the criteria,

so all 18 trials

were related to diuretics and B-blockers and were all
previously used in a meta-analysis study.

Data for the

study were gathered by Psaty and Nichols and "differences
were resolved by consensus"

(Psaty et al.,

1997, p.

740).

The clinical trials in the study were classified into
three treatment strategies,

as follows : "(1)

high-dose

diuretic therapy . . . doses greater than or equal to the
equivalent of 50 mg of chlorthalidone or
hydrochlorothiazide

(HCTZ),

(2) low-dose diuretic

. . .

the equivalent of 12.5 to 25 mg per day of chlorthalidone
or HCTZ,

and

(3) B-blocker therapy"

(Psaty et al.,

1997,

p. 740).

The ACE inhibitor and calcium channel blocker

trials were selected from "the largest and longest trials
evaluating surrogate endpoints
indicators

. . . for the special

[of myocardial infraction and stroke]

upon recent meta-analysis"

(Psaty et al.,

we relied

1997, p.

740).

All three treatment strategies of high-dose
diuretics,

low-dose diuretics,

and B-blocker decreased the

incidence of stroke in patients who had hypertension with
relative risks

(RR) of .49,

0.66,

and 0.71,

respectively.

The occurrence of stroke with the high-dose diuretics was
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significantly different from the use of B-blocker therapy
(p = .02), but was not significant in comparison to the
low-dose diuretic therapy.
disease,

In regard to coronary artery

which is a precursor to myocardial infarction,

high-dose diuretic therapy and B-blocker therapy had
similar RR of 0.99 and 0.93, but did not produce results
significantly different from the placebo.
diuretic therapy,

on the other hand,

Low-dose

was significant in

its ability to reduce coronary artery disease when
compared to the other two strategies mentioned with an RR
of 0.72 and a statistical significance to B-blockers of p
= .03 and high-dose diuretics

(p = .01)

(Psaty et al.,

1997).
Compelling clinical trials for ACE inhibitors and
calcium channel blockers were discussed by the author,

but

no meta-analysis was performed due to a lack of long-term
trials.

Instead,

the authors reviewed various clinical

trials in support of certain antihypertensives as firstline therapy in specific populations as recommended by the
JNC VI guidelines for hypertension treatment. Alarming
information on Nifedipine and short-acting calcium channel
blockers was discussed by the authors.

In six clinical

trials concerning the calcium channel blocker.

Nifedipine,

at a dose of 80 mg or more per day there was an increased
RR of mortality

(2.64,

95% Cl,

1.42 - 4.92)

associated
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with the therapy
Seattle,
author,

(Psaty et al.,

Washington,

1997). Also,

in the

case-control study mentioned by the

"short-acting calcium channel blockers were

associated with an increased risk of myocardial infarction
. . . than beta-blockers
(risk ratio,
et al.,

1.57;

[in]

95% Cl,

subjects with or without CVD

1.24 - 2.04; p < .001)"

(Psaty

1997, p. 743). One meta-analysis study on ACE

inhibitors'

effect on reducing mortality in patients with

congestive heart failure was reviewed by the author.
et al.

stated,

colleagues,

"In the meta-analysis by Garg and

the RR for total mortality was 0.77

0.58 - 0.83),

(95% Cl,

and the reduction was primarily due to fewer

deaths from progressive heart failure
0.58 - 0.83)"

Psaty

(RR, 0.69,

95% Cl,

(p. 742).

Although the authors did not do a meta-analysis of
data for ACE inhibitors and calcium channel blocker
clinical trials reviewed,

they make a strong statement in

favor of diuretics and beta-blockers rather than these
newer antihypertensives due to a lack of long-term
controlled clinical trials toward various and end-points
of cardiovascular disease prevention or progression.
et al.

Psaty

supported diuretics and beta-blockers as first-line

therapy by stating that.
Diuretics and B-blockers--inexpensive
antihypertensive agents— have been proven both
safe and effective in long-term trials . . . the
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clinical rationale for withholding safe,
effective, and proven therapies must be
compelling . . . the potential benefit of a
surrogate end point or a laboratory value must
be weighed thoughtfully against the known health
risks of withholding the proven first-line
therapies currently recommended by the JNC-V.
(Psaty et al., 1997, p. 744)
These findings supported the JNC VI guidelines that were
published in the same year,

as diuretics and beta-blockers

were still recommended as first-line treatments for
hypertension.
Another study found in the review of literature
supported the JNC VI recommendations to control blood
pressure of patients with hypertension to a level < 140/90
mmHg.

The Hypertension Optimal Treatment

(HOT)

randomized

trial sought to ascertain the association of intensive
blood pressure lowering regimens and cardiovascular
complications in hypertensive patients
1998).

(Hansson et al.,

The study wanted to see if there was a correlation

between lower diastolic blood pressure readings over time
and subsequent cardiovascular events.
The study was a randomized trial composed of 18,790
patients from 26 different countries.

The patients were 50

to 80 years in age, with a mean age of 61.5 years.

Each

person in the sample was randomly assigned to a target
diastolic blood pressure level of < 90 mmHg,

< 85 mmHg,

equal to 80 mmHg in the study in which half received

or
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acetylsalicylic acid
(Hansson et al.,

(ASA)

1998).

and the other half placebo

The countries for the study were

selected from the following four continents:
America,

South America,

Europe,

and Asia.

North

The sample was

followed up for cardiovascular events for an average of
3.8 years

(range 3.3 - 4.9)

(Hansson et al.,

1998).

Patients were treated in one of five different modes
to obtain the diastolic blood pressure level desired as
follows:
a day.

Step 1: felodipine

(calcium channel blocker)

5 mg

Step 2: ACE inhibitor or beta-blocker added to step

1, Step 3: titration of the dosage of felodipine to 10 mg
a day with ACE inhibitor or beta-blocker.

Step 4: doubling

the dosage of ACE inhibitor or beta-blocker in Step 2 with
felodipine,

and Step 5: adding a diuretic to ACE

inhibitor/beta-blocker and felodipine therapy in Step 4
(Hansson et al.,
measured using,
(Visomat OZ,
et al.,

D2,

1998, p.

1998).

Blood pressure measurements were

"an oscillometric semi-automatic device
International,

Hestia,

Ge rmany)" (Hansson

1756). The validity and accuracy of the

machine to measure blood pressures were "subjected to the
blood-pressure-measuring equipment proposed by the British
Hypertension Society and was found to meet those stringent
criteria"

(Hansson et al.,

1998, p. 1757).

For the purpose of the study, major cardiovascular
events were described as "fatal and non-fatal myocardial
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infarction
death"

(MI), all strokes and all other cardiovascular

(Hansson et al.,

1998, p. 1756).

Reported events

were gathered from hospital and physician records,
certificates,

and N. reports.

death

Fatal events were described

as death that occurred within 28 days of onset of a
cardiovascular event.

Silent Mis were also evaluated for

and were classified as a change of a new Q wave or QS
waves from a baseline ECG reading without the patient
portraying any signs or symptoms.
The study used a Poisson model to analyze the trends
of CV events between the different groups with assigned
target blood pressures.

Hansson and colleagues stated.

The logarithm of the hazard rate was modeled as
a continuous function of mean blood pressure by
connected linear and quadratic pieces in
specified intervals . . . time dependent
information was used for the covariants current
age, time from entry and blood pressure frame
every 6 months . . . two-tailed tests were used.
(p. 1757)
The researchers found that the patients who
participated in one of the five antihypertensive treatment
regimens had a reduction in their systolic and diastolic
blood pressure.

The antihypertensive regimens reduced the

average diastolic blood pressure
mmHg,

(DBP) by 20.3 mmHg,

22.3

and 24.3 mmHg and the average systolic blood

pressure

(SBP) by 26.2 mmHg,

28.0 mmHg,

the targeted DBP groups of < 90 mmHg,

and 29.9 mmHg in

< 85 mmHg,

and < 8 0
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mmHg;. respectively,
baseline

when compared to DBF levels at

(Hansson et al.,

1998) . There were very few

patients in the study with a DBF > 90 mmHg after receiving
antihypertensive treatment.
target group of < 90 mmHg,

Only 12%,

7%, and 6% of the

< 85 mmHg,

and < 80 mmHg had

DBF greater than 90 mmHg following treatment.
receiving Aspirin

(ASA)

The patients

therapy did not have a

significantly different average blood pressure reading
than those who did not

(142/83.2 mmHg vs.

141.4/82.9

m m H g ) . Fatients whose diastolic blood pressure

(DBF) was

controlled to < 85 mmHg and < 80 mmHg had significantly
reduced risks of certain cardiovascular

(CV) events when

compared to the group assigned a target blood pressure of
< 90 mmHg.

The events of all Mis were found to be reduced

by 25% in the group with a target DBF of < 85 mmHg and by
28% in the group with a target DBF of < 80 mmHg when
compared with the patients in the target DBF group of < 90
mmHg.
Diabetic patients had a marked reduction of CV events
in the group of < 80 mmHg when compared to the group of <
90 mmHg as target DBFs.
diabetes mellitus,

In 1,501 of the patients with

the risk of a major CV was found to be

50% less in the < 80 mmHg DBF group than those in the < 90
mmHg group.

The event of stroke in the diabetic patients

was also reduced in the target group with target DBF of
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< 8 0 mmHg by 30% when compared to the < 90 mmHg group
(Hansson et al.,

1998).

Another significant finding in the study was the
reduction in the incidence of stroke in patients with
previous ischemic heart disease with a 43% reduction in
the DBF target group of < 80 mmHg versus the DBF target
group of < 90 mmHg.

It is important to note that the

average DBF after treatment in the < 80 mmHg group was not
< 80 mmHg but 81.1 mmHg

( ^ = 5.3)

antihypertensive treatment.

following

The average DBF of the < 90

mmHg group and < 85 mmHg group after treatment was 85.2
mmHg

(S^ = 5.1)

and 83.2

In conclusion,

(S_D = 4.8),

respectively.

Hansson and colleagues asserted,

"intensive lowering of blood pressure in patients with
hypertension was associated with a low rate of
cardiovascular events

. . . the HOT study shows the

benefit of lowering the DBF down to 82.6 mmHg"
1755).

(1998,

p.

These findings support the JNC VI guidelines which

recommend that health care providers control their
hypertensive patients'

blood pressure to < 140/90 in

patients without target organ disease and < 130/85 mmHg in
patients with diabetes.

The JNC VI guidelines state that.

The goal of prevention and management of
hypertension is to reduce morbidity and
mortality by the least intrusive means possible
. . . this may be accomplished by achieving and
maintaining systolic blood pressure below 140
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mmHg and DBF below 90 mmHg and lower if
tolerated. (JNC VI, 1997, p. 19)
The results also support the JNC VI recommendation for
more aggressive treatment of hypertension in the elderly
to prevent fatal CV events,

as many of the patients were >

65 years of age with an average age of 61.5 years

(Range:

50 to 80).
Staessen et al.

(2000)

asserted that the results of

their study supported the JNC VI guidelines concerning the
treatment of systolic blood pressure to a level to prevent
target organ damage

(Staessen et al.,

1998).

These

researchers were interested in the outcomes of treated and
untreated isolated systolic hypertensive patients.

The

study was a meta-analysis study that focused on outcome
trials concerning isolated systolic hypertension

(ISH)

and

subsequent associated risks.
The sample of patients to be analyzed in the m e t a 
analysis was formed samples from eight total trials
reviewed.

Three studies were outcome trials directly

related to ISH. The five other trials were outcome-based
hypertension trials that included ISH patients as a
subgroup.

A total of 15,693 patients from the eight

clinical trials were included in the meta-analysis group.
The majority of the patients in the study,
China trial,

excluding the

were female and had an average age of 70
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years

(Range:

sample,

60 to 760).

Smokers composed 15.8% of the

and 30.9% of the sample had one or more

cardiovascular complications before their individual trial
began.

Concerning those patients with previous

cardiovascular disease or complications,

4.5% had a

stroke,

(MI),

7.4% had a myocardial infarction

symptoms of angina,

14.2% had

and 33% had ECG changes that were

indicative of left ventricular hypertrophy

(Staessen et

a l . , 1998).
These authors defined ISH as a systolic blood
pressure > 160 mmHg with a diastolic pressure of < 95
mmHg.

The outcome criteria that were evaluated for

regarding their association with ISH were as follows:
total and cardiovascular mortality,
complications,

(c) stroke,

(Staessen et al.,

and

(a)

(b) cardiovascular

(d) coronary events

2000).

In analysis of the eight different outcome trials
concerning ISH,

the researchers used "nonparametric

methods and Cox regression to model the risks associated
with blood pressure and to correct for regression dilution
bias"

(Staessen et al.,

2000, p. 865). Various

antihypertensive drug regimens were used in each trial
analyzed to reach target blood pressures and all trials
were controlled.

In the Cox regression statistical method,

used by the researchers,

age,

sex,

and systolic and
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diastolic blood pressures at baseline were explanatory
variables.

Correction for regression dilution bias was

estimated by the researchers using a "cohort of patients
randomized to no treatment who accumulated an event free
survival for two years"

(Staessen et al.,

2000,

p.

866).

The researchers "calculated relative benefit as the
percentage reduction in the outcome rates in the active
treatment group compared with the rate in the control
groups

. . . absolute benefit with

et al.,

2000, p.

[a]

95% Cl"

(Staessen

866).

The researchers found a reduction of overall
m ortality and cardiovascular events.

One significant

result was the risk of total mortality associated with ISH
was less than that of diastolic hypertension at the
beginning of the trial before a treatment plan was started
(£ = .001 vs. £ = .05, respectively). Analysis of the four
outcomes,

previously stated,

after pharmacologic treatment

with antihypertensives was significant as well.
a 13%

There was

(2-22, £ = .02) reduction in total mortality in

patients with a treated systolic blood pressure

(SBP)

level < 160 mmHg when compared to the control group and an
18%

(4-29, £ = .01)

death.
mmHg,

Patients,

reduction in cardiovascular related

in the trials treated to a SBP < 160

also produced a total pooled result of a 26%

£ < .001)

(17-34,

reduction in cardiovascular complications,

a 30%
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(18-41, £ < .001)
= .001)

reduction of stroke,

and a 23%

(10-34, £

reduction in coronary events when compared to the

control group

(Staessen et al.,

2000).

Staessen and colleagues stated after interpretation
of the results that,

"Drug treatment is justified in older

patients with isolated systolic hypertension where
systolic blood pressure is 160 mmHg or higher"
et al.,

2000, p. 872).

(Staessen

This study's results and

interpretations support the JNC VI guidelines published in
1997 which support a more aggressive treatment of
hypertension in elderly patients to reduce subsequent
cardiovascular mortality and target organ disease.

The

study provided significant results that support previous
research that a treatment regimen to reduce ISH reduces
the risk for cardiovascular mortality and events as
recommended by the JNC VI guidelines which affirms
The goal of treatment in older patients should
be the same as in younger patients (to below
140/90 mmHg if at all po ss ib le ), although an
interim goal of systolic blood pressure below
160 mmHg may be necessary in those patients with
marked systolic hypertension. (JNC VI, 1997, p.
46)
Another clinical trial supports the JNC VI guidelines
in regard to its special recommendation to use ACE
inhibitors to treat hypertension in diabetic patients.

The

clinical trial performed by Morgenson studied the effects
of the ACE inhibitor lisinopril and Candesartan on the
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outcome variables of blood pressure and microalbuminuria
(Morgenson,

2000).

The clinical trial,
parallel group,

a prospective,

double blind study,

randomized,

was performed in 37

hospitals/primary care centers in Australia,
Finland,

and Israel

(Morgenson,

Denmark,

2000). The population from

which the sample was chosen was type 2 diabetics who had
previously been diagnosed with hypertension and
microalbuminuria.

The sample was composed of 199 type 2

diabetics with a mean age of 60 years
had the following criteria:

(Range:

30-75)

and

(a) urinary albumin :

creatinine ratio of 2.5 - 25 mcg/mmol after 2 weeks of
placebo treatment and

(b) a diastolic blood pressure of 90

- 110 mmHg following both 2 and 4 weeks of placebo
treatment

(Morgenson,

2000). Two patients were excluded

from the study due to refusal to take treatment regimen
leaving 197 patients who actively received treatment.
Criteria used to exclude people during the sampling
process were as follows:
40 kg/m2,

(a) a body mass index

(BMI)

(b) a systolic blood pressure > 200 mmHg,

non-diabetic cause of secondary hypertension,

of >
(c) a

(d) a serum

creatinine level of 130 x 6 dmol/L in women and 150 x 6
dmol/L in men,

(e) a serum potassium level > 5.5 mmol/L,

(f) a hemoglobin A^^ of greater than 10%,
actual pregnancy,

and

(g) potential or

(h) patient breast-feeding
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(Morgenson,

2000,

p. 1442).

Patients taking lisinopril

only during the study were by majority male
compared to women

(N = 62)

(N = 36) and had a mean BMI of 2 9.8

kg/m2,

a mean systolic blood pressure of 162.6 mmHg

17.6),

and a mean diastolic blood pressure of 95.7 mmHg

(SD = 6.2 mmHg)
average,

before treatment.

The patients,

had been diabetics for 8.4 years

hypertensive for 9.0 years

(SD = 8.9).

(^

(^

=

on

= 7.3)

and

These patients also

had a mean urinary albumin :creatinine ratio of 6.6
mcg/mmol
1.6%).

(^D = 1.1)

and a mean hemoglobin

of 7.6%

(SD =

Fourteen of the 197 randomized patients who

underwent active treatment dropped out due to bothersome
side effects,
dizziness,

with the main adverse side effects of

feeling weak,

or both

(Morgenson,

2000).

The methods of the study included an antihypertensive
regimen of either lisinopril,

Candesartan,

or combination

over 24 weeks while evaluating each regimen's effect on
the outcome criteria of hypertension and m i c r o a l b u m i n u r i a .
Baseline hypertension levels and urinary
albumin :creatinine ratios were drawn and evaluated and
evaluated again at 12 weeks and 24 weeks post-treatment.
The post-placebo/treatment phase consisted of two phases
of treatment.

In the first phase of treatment the sample

was divided into two groups.

The first group received

lisinopril treatment only for 12 weeks and the second
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group,

Candesartan,

for 12 weeks.

The second phase of the

treatment regimen lasted from the 12^^ week to the 24^^
week and split the sample into three groups.
group was treated with lisinopril only.
was treated with Candesartan only.

The first

The second group

The third group was

treated with a combination of lisinopril and Candesartan
as long as the patient had a diastolic blood pressure > 80
m mHg at 12 weeks following their previous treatment
regimen.

The daily dose of Candesartan used was 16 mg,

and

the daily dose of lisinopril was 20 mg.
Blood pressure measurements were taken in the arm
with each patient resting for 5 minutes at approximately
24 hours post-treatment with antihypertensive medicine.

An

automated blood pressure machine was used to take
measurements.

Three blood pressure measurements were taken

sitting and averaged and then one measurement after
standing for 1 min. A total of nine blood pressure
measurement sessions were performed during the study.
Three sessions were conducted before treatment to produce
an established baseline blood pressure.
Microalbuminuria was measured through urinary
albumin :creatinine ratios.

The urine samples used for

ratios were spot samples taken on two consecutive days by
the patients in the morning and brought to the clinic
where serum creatinine levels were drawn.

These
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microalbuminuria results were performed before treatment
as a baseline measurement and then reevaluated at 12 and
24 weeks.

Urinalysis,

hematology,

and hemoglobin

measurements also were taken at baseline,

12 weeks,

and 24

weeks.
The researchers used a linear model for analysis of
covariance when averaging the change of microalbuminuria
from baseline at 12 weeks and 24 weeks

(Morgenson,

2000).

The analysis of covariance used "factors for treatment,
centre,

and interaction between them . . . changes in

diastolic blood pressure and body weight
covariates"

(Morgenson,

...

as

2000, p. 1442). The results were

shown as "estimates of the true geometric means and as
estimates of ratios of the true geometric means,

with

their 95% confidence intervals and corresponding £ values"
(Morgenson,

2000,

p. 1442).

Patients treated with lisinopril only achieved a 9.7%
(7.9 - 11.5, £ < .0001)
pressure,

a 15.7%

reduction in sitting diastolic

(12.2 - 19.2, £ < .001)

sitting systolic pressure,

and a 46%

reduction in

(35 - 56, £ < .001)

reduction in microalbuminuria at 12 weeks post-treatment
with a 20-mg daily dose. Outcomes at 24 weeks were also
significant with a 10.7%

(8 - 13.5, £ < .001)

sitting diastolic blood pressure,
< .001)

a 16.7%

reduction in

(11.4 - 21.9, £

reduction in sitting systolic blood pressure,

and
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a 39%

(20 - 54, £ < .001)

reduction microalbuminuria.

The

researcher stated that the best results for the study came
from patients receiving the combination therapy of
Candesartan and lisinopril but were not reproduced here
due to Candesartan not being an ACE inhibitor and
therefore not recommended by the JNC VI recommendations
which concluded that,

"in patients with diabetic

nephropathy ACE inhibitors are preferred"

(NHLBI,

1997, p.

49) .
The author concluded that.
Recent guidelines for blood pressure targets in
diabetic patients have emphasized the importance
of aggressive blood pressure reduction in
diabetic patients with evidence of renal disease
. . . our results show that dual blockade of
renin-angiotensin system particularly effective
in decreasing blood pressure in these patients
and supports this . . . therapeutic approach for
the prevention of diabetic renal and vascular
disorders. (Morgenson, 2001, p. 1444)
Lisinopril treatment alone,

however,

was also very

effective in its blockage of the renin-angiotensin system
and produced significant effects in decreasing
hypertension microalbuminuria.

This study further supports

the studies reviewed by the JNC VI which recommended ACE
inhibitors as the preferred treatment regimen for diabetic
hypertensive patients to prevent future cardiovascular
disease and diabetic complications such as nephropathy.
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Although the review of the literature was not
exhaustive in nature,

it is sufficient in its ability to

support a need for further dissemination of the JNC VI
guidelines.

It also supports the need for further research

for compliance with these guidelines in the future.

The

recently published studies reviewed here further support
the validity of the research-based JNC VI guidelines
published in 1997. The review of literature chosen for
this study was chosen by the researcher for strength to
support the JNC VI guidelines and ability to support the
tool used for measuring compliance with the JNC VI
guidelines in this study.

Chapter III
The Method
This researcher was concerned with evaluating primary
care nurse practitioners'

(PCNPs)

compliance with the JNC

VI guidelines in the management of hypertension and will
be used to formulate strategies to increase compliance
with theses guidelines in the future to ensure evidencebased medicine in the treatment of this national health
concern.

Design of the Study
The researcher used a descriptive design to define
the implementation of the sixth edition of the Joint
National Committee guidelines

(JNC VI)

for hypertension

management in p r a c t i c e . A descriptive design was
appropriate because its focus is on "the frequency of
occurrence" in variables and does not seek to form
relationships between variables
196).

(Polit & Hungler,

1999,

This researcher sought data for explaining P C NP s'

use of the guidelines established by the JNC VI, and not
to determine any relationship to actual blood pressure
readings as an evaluation of hypertension management.
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p.
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These data were easily analyzed and disseminated back to
PCNPs in practice with this design and was considered
important to the researcher so PCNPs could critique their
hypertension management strategies in an effective and
timely manner.

Setting,

Population,

and Sample

S e t t i n g . The settings for the study were various
outpatient,

primary care practice sites within the states

of Mississippi,

Alabama,

Tennessee,

and Louisiana.

Each

primary care practice had at least one PCNP who treated on
average at least 5 hypertensive patients per day.

Sites

were obtained by assessing the qualifications of each PCNP
through a self-report survey included in the study.
that were reported were as follows:
(b) free clinic,

Sites

(a) hospital clinic,

(c) health department,

and

(d) private

practice.
P op u l a t i o n . The population for the study were
advanced practice nurses,

who were licensed and certified

in the states of Mississippi to practice in the role of an
PCNP.

The PCNPs were experienced in treating adult

hypertensive patients,

had at least 1 year of experience

as a family nurse practitioner
nurse

(FNP)

or advanced practice

(ANP), and worked in outpatient settings as a

primary care provider in the states of Alabama,

Louisiana,
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Tennessee,

and Mississippi.

The specific population from

which the sample was drawn was a database of FNPs and ANPs
certified within the state of Mississippi containing over
600 names of PCNPs.

For subjects to be included in the

study they had to see and treat,

on average,

a minimum of

at least 5 hypertensive patients per day and was assessed
for by s el f- re po rt .
S a m p l e . The sample for the study was achieved using a
systematic random sampling design until 200 prospective
subjects were garnered.

The sample was selected from an NP

database obtained from the Mississippi Board of Nursing as
the sampling frame by using a computer-generated table of
random numbers.

PCNPs who did not work in an outpatient

setting or see at least 5 hypertensive patients per day
were excluded from the sample when data were returned by
assessing this criteria on a self-reported demographic
data sheet returned by mail.

The final sample included

those subjects who met the criteria and returned Cagle's
JNC VI Guidelines Compliance Survey

(see Appendix A) to be

included in the study.

Instrumentation
Cagle's JNC VI Guidelines Compliance Survey was used
to assess the PCNPs'

implementation of the JNC VI

guidelines in p r a c t i c e . The tool was vignettes developed
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by the researcher to evaluate PCNPs'
and practices in hypertension care,

beliefs,

knowledge,

especially

hypertension management strategies that are recommended by
the JNC VI.

These vignettes were case studies about

hypertension management situations that included patients
with varying co-morbidity.

The vignettes focused on both

essential hypertension and hypertension that could be
secondary to disease process.
to evaluate PCNPs'

The vignettes were developed

treatment practices by having the PCNPs

write out interventions for each case study in three
areas:

(a) pharmacologic,

(b) non-pharmacologic,

and

(c)

labs and procedures that could be ordered by the FNP in
the management of hypertension.

The labs or procedures

(area c) could be checked if the PCNP believed they were
needed and there was a space for the PCNPs to write in any
labs or procedures that they felt would be necessary in
managing the patient's hypertension. All labs and
procedures that are recommended by the JNC VI guidelines
for each case study were provided as a choice along with
other tests that are not recommended.
Ten critical factors,
recommendations,

JNC VI guidelines

were identified and chosen as essential

for competent hypertension management practice for the
areas of

(a), (b), and

(c). Scoring of the vignettes were

performed by evaluating the frequency of JNC VI guidelines
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interventions chosen or written in by the PCNPs in regard
to each case study.
The second case study was scored by giving one point
in the pharmacologic area for starting this patient on an
ACE inhibitor,

ACE inhibitor plus diuretic,

the dose of her hydrochlorothiazide

(HCTZ)

or increasing
due to the

patient's past history of left-sided heart enlargement
(probably left ventricular hypertrophy)

and supporting

symptoms of shortness of breath with activity.

Beta-

blockers are contraindicated due to her history of COPD,
and calcium channel blockers are not as effective in
preventing the occurrence of congestive heart failure like
ACE inhibitors.

The JNC VI

(NHLBI,

1997)

guidelines state.

Some patients with hypertension (current or
past) develop heart failure with a normal
ejection fraction, implying diastolic
dysfunction . . . the Framingham Heart Study
have demonstrated that hypertension continues to
be the major cause of left ventricular failure .
. . dihydropyridine calcium antagonists [Lotrel]
and Felodipine have been demonstrated to be safe
in treating angina and hypertension in patients
with advanced left ventricular dysfunction when
used in addition to ACE inhibitors, diuretic, or
digoxin . . . other calcium antagonists are not
recommended in these patients, (p. 47)
One point was awarded in the non-pharmacologic area
if lifestyle modifications were addressed including at
least counseling on a healthy heart diet.

One point was

awarded in the diagnostic tests/lab area if the PCNP
ordered at least the following tests:

urinalysis.
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electrolytes,

EKG,

and a lipid profile.

The JNC VI

guidelines recommend limited echocardiography in patients
with LVH due to cost and an EKG can detect its presence.
The PCNPs were not penalized for ordering an
echocardiogram

(Echo)

due to the patient's complaints of

shortness of breath and 3 years since last Echo. Although,
requesting the old echo and a full cardiovascular
examination may eliminate the need due to no shortness of
breath at rest and would surely benefit this grandmother
on Medicaid by saving her the money of an unwarranted
Echo.

The PCNPs were not penalized for not including a

urinalysis as long as they spoke to getting electrolytes
with BUN/creatinine or similar profile.

Other tests may

have been warranted and ordered to help with the clinical
picture,

but the diagnostic tests/labs chosen were

considered critical test/labs to be ordered due to this
patient being on a diuretic. Also,

this patient needed her

renal function checked before starting an ACE inhibitor,
an EKG to confirm LVH and rule out

any myocardial

infarction,

assess for

and a lipid profile to

hyperlipidemia as a future MI risk

factor that can

controlled.

recommended asroutine

All of these tests are

be

tests to be run before starting antihypertensive
pharmacologic treatment by the JNC VI

(NHLBI,

1997).
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The third and last case study was scored by giving
one point in the pharmacologic area for the following : (a)
changing the patient to another ACE,
ACE 4- diuretic,
antagonist,

or

(b) change to another

(c) change to Angiotensin II receptor
(d) placing the patient on a calcium

antagonist plus ACE inhibitor.

The main result to achieve

in this patient and gain a point was renoprotection.

The

JNC VI guidelines state that ACE inhibitors are the
preferred antihypertensive agent for diabetics to prevent
diabetic nephropathy and for this reason should not be
removed from this patient even though other medicines
offer some renoprotection. ACE inhibitors also may have a
favorable effect on patients with the co-morbid condition
of renal insufficiency,

which is a possibility with this

noncompliant African American diabetic whose blood sugar
and diet are uncontrolled.

The patient has a family

history of renal failure and has symptoms of polyuria
which,

although is probably related to his diabetes,

also a symptom of acute renal failure/insufficiency.
JNC VI states.
Hypertensive nephrosclerosis is among the most
common causes of progressive renal disease,
particularly in African Americans . . .
impressive results have been achieved with ACE
inhibitors with type 1 diabetic nephropathy, in
patients with proteinuria greater than 1 gm in
24 hours, and in patients with renal
insufficiency . . . consequently, patients with
hypertension who have renal insufficiency should

is
The

62

receive, unless contraindicated, an ACE
inhibitor in most cases, along with a diuretic
to control hypertension and slow progressive
renal failure. (NHLBI, 1997, p. 48)
Calcium channel blockers by themselves and beta-blockers
were considered to be inadequate treatment due to JNC VI
r ec om me n d a t i o n s .
Consideration was given on whether or not to include
long-acting,

once-daily-dosing as criteria to receive the

point in this category,

but was eliminated due to the

alteration in response that was expected in return of the
survey.

The researcher would have had difficulty

ascertaining if once-daily-dosing was implied with
medication change or combination agents and specific
instructions on prescription were not given to guide this
response.
The nonpharmacologic area was scored by receiving one
half point for the following interventions : tobacco
cessation and alcohol moderation.

One point was received

for diet modification that included a low-sodium diet
g / d a y ) . The JNC VI asserts that.
Excessive alcohol intake is an important risk
factor for high blood pressure, can cause
resistance to antihypertensive therapy and is a
risk factor for stroke . . . alcohol should be
[limited daily to] no more than 1 ounce of
ethanol . . . or 2 ounces of 100 proof whiskey .
. . such amounts do not raise blood pressure and
have been associated with a lower risk of CHD.
(p. 21)

(< 3
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The JNC VI als© states that,
African Americans, -older people, and patients
with hypertension or diabetes are more sensitive
to changes in dietary sodium chloride . . .
meta-analysis of clinical trials reveals that a
reduction of 75 to 100 mmol in sodium intake
lowers blood pressure over periods of several
weeks to a few years . . . [and one m e t a 
analysis found that] patients age 45 or older
with hypertension found an average decrease of
6.3/2.2 mmHg with a urinary sodium reduction of
95 mmol per day. (p. 21)
Concerning the tobacco cessation intervention,
JNC VI states that,

the

"Cigarette smoking is a powerful risk

factor for cardiovascular disease,
tobacco in any form is essential

and avoidance of

. . . the cardiovascular

benefits of discontinuing tobacco use can be seen within a
year in all age groups"

(NHLBI,

1997, p. 23). These JNC VI

recommendations are critical factors for this African
American patient who binge drinks on the weekends,

smokes,

and seems to be noncompliant with his diabetic diet and
treatment regimen.
The diagnostic/labs intervention area was scored by
awarding 1 point for ordering the following tests/labs :
urinalysis,

fasting glucose,

protein/creatinine clearance,

lipid profile,
electrolytes,

24-hour urine
and EKG.

PCNPs

were not penalized for not ordering a fasting blood sugar
if they ordered an HgbA^c or a metabolic profile which
included a serum glucose.

These are better tests to

measure diabetic compliance than a fasting blood sugar.
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The PCNPs also were not penalized for not ordering a 24hour urine if they spoke to assessing the urinalysis
first,

ordered an electrolyte profile with BUN/creatinine,

or ordered a 24-hour urine for microalbuminuria.

These

tests were considered critical labs to order for this
patient due to his presentation and medical and family
history.
The vignettes were assumed to have face value
validity in assessing PCNPs'

use of JNC VI guidelines in

practice as agreed upon by the researcher and three other
FNPs with hypertension management education.

The FNPs

chosen for peer review of the vignettes for content
validity each had over 5 years of experience as an FNP and
were familiar with the JNC VI guidelines.

The vignettes

were peer reviewed for readability and comprehension by
the FNPs previously mentioned and 28 FNP students at the
Mississippi University for Women.

Methods of Data Collection
The research study proposal was first submitted for
approval by the Mississippi University for Women's
Committee on Use of Human Subjects in Experimentation to
gain acceptance of the study in regard to confidentiality
and beneficence to participants and the overall benefits
and risks

(see Appendix B ) . Following approval,

the
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database/PCNP list was secured from the Mississippi Board
of Nursing. After obtaining an adequate random sample of
200 PCNPs for the study,

a point of contact for each PCNP

was established via the database used in the sampling
process.

Each prospective participant was sent a packet

including a cover letter

(see Appendix C) describing the

study and the Cagle's JNC VI Guidelines Compliance Survey
and a self-addressed,

stamped envelope.

Each prospective

PCNP was informed that return of the survey included would
imply consent to participate in the study.

Each cover

letter also included the researcher's address,
number,

telephone

and e-mail address so each PCNP could have access

to the researcher for any questions regarding the study.
Two weeks following the first mailing,

a second

correspondence was sent including a reminder letter for
participation

(see Appendix D ) . An additional question was

sent following the second mailing on a self-addressed,
stamped postcard

(see Appendix E ) . The final question was

as follows : Are you aware of the current national
guidelines

(JNC VI)

for hypertension management? This

question was used to assess awareness and need for further
dissemination of the JNC VI guidelines to PCNPs in
practice and insight as possible explanation for some PCNP
noncompliance with the JNC VI guidelines.

The question was

mailed with the last survey and was returned with a self
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addressed,

stamped envelope.

The participants were

informed to return mailings without their name or address
to ensure confidentiality.
These data were analyzed using descriptive statistics
and disseminated back to PCNPs who participated in the
study at their discretion.

Information on how to obtain

the results of the study and the JNC VI guidelines was
made available to the PCNPs who participated in the study
at their request by contacting the researcher via phone or
E-mail.

Data Analysis
Data returned from the vignettes,

as provided by the

PCNPs in the study, were analyzed using univariate
descriptive statistics,

such as frequency distribution of

scores and the variability of individual scores in the
form of range and standard deviation.

There were 10

critical factors/JNC VI guidelines to be measured by the
vignettes provided to the PCNPs in the study.

Each

critical factor received a score of +1 if written in or
chosen as an intervention with 0 being the lowest
individual score obtainable and 10 being the highest.

The

group mean score of all the PCNPs multiplied by the number
of PCNPs in the study

(N = 200) was obtained and divided

by the total best possible score of 2,000 to elicit a
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percentile grade for the sample.

The best case percentile

score and worst case percentile score also were reported.
The FNPs were required to get all critical factors correct
for each case study to be considered completely compliant
in implementing JNC VI guidelines for the particular case
study and a minimum of two to three critical factors for
each case study to be considered partially compliant.

This

equaled an overall score of 10 for participants who were
considered completely compliant with JNC VI guidelines and
a score of 7 to 9 considered partially compliant. Any
score of less than 2 critical factors for one individual
case or an overall survey score of less than 7 was
evaluated as noncompliance with the JNC VI guidelines in
treatment.

The number of PCNPs who fell into each category

of compliant,

partially compliant,

or noncompliant were

reported in number and as a percentile of the total sample
for each case study and the total study.

Finally,

the

range between the lowest individual score and the highest
individual score,

along with a measurement of standard

deviation in scores,

were obtained to show the degree of

homogeneity in scores.

This procedure was used to assess

the validity of the survey in producing scores that would
implicate a high degree of homogeneity in comprehension
and use of the survey to provide data for the study.
Results were checked for accuracy by a research committee
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and were provided in both narrative form and in the form
of tables to enhance comprehension of the data by
consumers of the research in the future.

Chapter IV
The Findings

This study,

which was concerned with primary care

nurse practitioners'

(PCNPs)

compliance with the JNC VI

guidelines in the management of hypertension,
survey method to gather data for analysis.

used a

The data

returned via the Cagle's JNC VI Guidelines Compliance
Survey were scored using 10 critical factors/JNC guideline
parameters established for each case study.

Three

points/parameters were allotted for the first two case
studies and 4 points for the last case study.

One

point/parameter was available for each case study
intervention area of pharmacologic,
diagnostic tests/labs,

non-pharmacologic,

and

except for Case #3 which had two

points available in the non-pharmacologic intervention
area.

Data collection began on May 30, 2001,

June 16, 2001.

and ended on

This chapter is focused on PCNPs'

compliance with JNC VI guidelines and contains the
demographic,

descriptive data concerning the sample and

analysis of the results of the returned Cagle's JNC VI
Guidelines Compliance Survey.
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Description of the Sample
The Cagle's JNC VI Guidelines Compliance Survey was
returned by 53

(26.5%)

the 53 respondents,

16

PCNPs out of 200 surveys mailed.
(37%)

Of

of the PCNPs had to be

eliminated from participating in the study due to not
meeting the requirement of treating,

on average,

at least

5 hypertensive patients a day. The final sample of PCNPs
(N = 37) were by majority master's prepared
94.6%)

(n = 35,

and had < 5 years of experience as a primary care

practitioner

(n = 22,

61.1%).

worked in a private practice
hospital clinics
departments,

The majority of the PCNPs
(n = 24,

64.9%),

(n = 10, 27%) and free clinics,

community clinics

(n = 6, 16.2%).

years of experience of the PCNPs was 5.5 years
25,

SD = 2.1)

followed by
health

The average
(Range:

1-

with only three PCNPs having more than 10

years of experience.

Results of Data Analysis
A total score of 10 was considered to be compliance
with the JNC VI guidelines,

and a score of 7 to 9 was

partial compliance. Any score less than 7 was considered
noncompliance in the use of JNC VI guidelines for treating
hypertensive patients.
Only 10

(27%)

of the 37 PCNPs were partially

compliant with a score of 7 to 9. This left the majority
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of the PCNPs

(n = 27,

73%)

scoring less than 7 and

considered noncompliant with the JNC VI recommendation in
the management of hypertensive patients.

The best total

survey score was 9 (10.8% of the sample scores),
worst total case score was 2

and the

(5.4% of the sample s c o r e s ) .

The total distribution of scores can be seen in Figure 1.
Since the total average score for the 37 PCNPs in the
sample was 5.9

(Range:

2-9,

= 1.82),

determined that nurse practitioners

the researcher

(NPs)

compliant with the JNC VI guidelines,

are more

therefore are not

effectively employing them.

S co re s

7

10 13 16 19 22 25 28 31 34 37

0 Individual PCNP Scores
0 Average Total Score
□ Standard Deviation

Figure

1.

D i st r ib u t i o n of scores.
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The average total score for PCNPs who worked in a
private practice setting and worst clinical site score was
5.6

(Range:

5, 20.8%)

2-9,

= 1.90),

with only a small number

(n =

earning a partially compliant score of 7 to 9.

The average total score for the PCNPs in the hospital
clinics and best clinical site score was 6.7
SD = 1.7), with only 4 (40%)
higher and being compliant.
of health departments,

(Range:

4-9,

of the PCNPs scoring a 7 or
The rest of the clinical sites

community clinics,

free clinics,

and other clinical sites were grouped together due to the
small number

(n = 6). These clinical settings had a total

average survey score of 5.8
(33.3%)
2,

(Range : 5-8, ^

of the 6 PCNPs scoring a 7 or higher

3, and 4).

s

8
CO

1 2 3 4 5 6 7 8 9
PCNPs (1-10)

10

0 PCNP Scores/Hospital Qinic (PCNPs ( 1- 10))
0 Standard Deviation
□ Average Total Score

Figure 2 . Clinical Sites

- Hospital

= 1.3),

with 2

(see Figures
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Scores

1

3

5

7

9

11

13

15

17 19 21

23

PCNPs (1-24)
g^PCNP Scorës/FŸivatë^
R-actice
0 Average Total Score

j
,

□ Standard Deviation

Figure

3. C l i n i c a l

s i t e s - p r i v a t e practice.

2
8

( /)

P C N % (1-6)

0 PCNP S cores/A il
Other Clinics
0 Average Total
Score
□ Standard
Deviation

!
j
!
!
i

Figure 4. Clinical setting-all other settings
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PCNPs with over 5 years of experience

(n = 14,

38.9%)

scored higher than their peers with < 5 years experience
(n = 22,
(Range:

61.1%)
4-9,

with an average total survey score of 6.9
= 1.5). The less experienced PCNPs with <

5 years of experience as an PCNP had a total average
survey score of 5.3

(Range : 2-9,

SD = 1.8) . The PCNPs with

more than 5 years of experience were twice as likely to
obtain a score of competence

(n = 6, 42.9%)

less experienced colleagues

than their

(n = 4, 18.2%).

The best overall average,

case

study score was

obtained in Case Study #1, with a score of 2.4
3, ^

= 0.6)

and 18

(48.6%)

(Range:

1-

of the PCNPs receiving a score

of a 3 which was considered to be compliant with the JNC
VI guidelines for the case study. The worst overall,
average case study score was obtained on Case Study #3,
with a score of 1.9

(Range:

0-4, ^

= 1.1). A score of a 4

was needed to be completely compliant with the JNC VI
guidelines and a score of a 3 for partial compliance.
a few

(n = 3, 8.1%)

Only

received a score of a 4 and were

totally compliant with the JNC VI guidelines chosen to
score the case study. Only 8 (21.6%)
and were partially compliant.

received a score of 3

The second case study also

had a high degree of noncompliance with a
less

(n = 17,

50%),

and the average

score of 2 or

total score for this
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case study was 1.6

(Range:

0-3, ^

= 0.9)

6, and 7),

49%
46%

0 Percentage PCNPs - Compliant
0 Percentage PCNPs - Partially
Compliant
□ Percentage PCNPs -Non-compliant

Figure

5. Case

study #1.

16%

46%

38%
0 Percentage PCNF^ Compliant
0 Percentage PCNF^ Fbrtially Compliant
□ Percentage PCNPs -NonCompliant

Figure 6. Case study #2

(see Figures 5,
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8%
22%

70%
gg Perecentage PCNPs
- Com pliant
0 Percentage PCNPs ■
P artially Compliant
□ P ercentage PCNPs ■
Non-Compliant

Figure

7. Case

study #3.

Only 16 of the PCNPs returned the postcard answering
the question of whether or not they were aware of the JNC
VI guidelines.

Of these,

12

(75%)

stated they were aware

of these guidelines for hypertension management.
Concerning PCNPs'

ability to use the JNC VI guidelines in

anti-hypertensive prescriptive practice,
(50%)

5 (13.9%)

and 18

of the PCNPs were totally compliant or partially

compliant with the JNC VI guidelines in the prescription
of anti-hypertensive medications,

respectively,

with a

score of a 2 or a 3 out of 3 in this area leaving 13
of the PCNPs scoring less than a 2 in this area
Figure 8).

(see

(36%)
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# of P C N P s

Q PC N ft -R'escriptive Complaince
[5/36)
0 PCNFs - Partial Prescriptive
Compliance (18/36)
□ PCNPs- Prescriptive NonCompliance (13/36)

Figure 8. Prescriptive compliance with JNC guidelines

Chapter V
The Outcomes

This study was interested in assessing how well
primary care nurse practitioners
hypertension,

(PCNPs)

are managing

as current researchers have indicated that

m any health care providers have not been successfully
m anaging hypertension at a level to prevent target organ
damage over time
Perry et al.,
providers,

(Berlowitz et al.,

1998;

Swales,

1998;

Dustan,

1998;

1999). As health care

PCNPs are managing hypertension daily,

but

their compliance to the JNC VI guidelines of hypertension
management,

as a cohort,

had not been studied.

This study

was performed to add to this lack of research regarding
hypertension management by PCNPs.
This researcher sought to answer the two following
research questions:
1. How effectively are primary care nurse
practitioners

(PCNPs)

implementing the JNC VI guidelines

for hypertension management in practice?
2. Are PCNPs aware of the current national guidelines
(JNC VI)

for hypertension management?
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The Cagle's JNC VI Guidelines Compliance Survey
Survey)

and a question concerning PCNPs'

(CJGC

awareness of the

JNC VI guidelines were mailed to 200 prospective
participants/PCNPs and returned via mail to obtain the
data necessary to answer these two research questions.
The sample was composed of family nurse
practitioners

(FNPs)

and adult nurse practitioners

(ANPs)

with at least one year of experience in hypertension
treatment who were certified and licensed in the state of
Mississippi,

performing the role of a PCNP,

Mississippi,

Alabama,

Tennessee,

in

or Louisiana.

Out of the

200 CJGC Surveys sent to the 200 prospective PCNPs,
were returned by PCNPs,

54

of which 37 met the criteria for

inclusion in the study.
The majority of the PCNPs

(73%) were noncompliant

with the JNC VI guidelines in their treatment regimens,
although they were aware of these guidelines as
recommendations in the treatment of hypertension.
total average score on the CJGC Survey was 5.9
9, SD = 1.82)

The

(Range:

2-

out of a possible perfect score of 10. The

m in i m u m score for partial compliance on the CJGC Survey
was 7 out of 10, with a score of 10 being total compliant.
Adherence to the JNC VI guidelines was not due to a lack
of knowledge because 75%

(N = 12) of the PCNPs

(N = 16)
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reported that they were aware of this most recent edition
of the JNC VI guidelines of hypertension management.

Discussion
The researcher realized that many things influence an
PCNP's clinical decision-making skills concerning the
treatment of the hypertension patient,

which could

possibly affect the PCNPS responses on the CJGC Survey
toward a score of noncompliance.

The survey was not

labeled as the CJGC Survey as this would have produced
biased responses.

The PCNPs were informed that the case

studies provided in the survey were being used to assess
how PCNPs approach hypertension treatment daily without
regard to any insight that their treatment regimens were
being reviewed for compliance with the JNC VI guidelines.
This approach was crucial to prevent unbiased responses.
The researcher was aware that extraneous circumstances
could predispose the PCNP to respond to the CJGC Survey in
a manner that would produce a score of noncompliance
although the PCNP is aware that the JNC VI guidelines
exist.

These extraneous circumstances are briefly

discussed here to aid the reader in an accurate and more
meaningful interpretation of data.
The JNC VI guidelines,

although scientifically backed

and considered to be sound competent management
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recommendations in the treatment of hypertension by
experts in the field of hypertension management,
recommendations.

They are not laws and are not the sole

measures of competent treatment of hypertension,
clinicians'

are just

as the

judgment should be the deciding factor in

producing a treatment regimen that is based upon the
assessment of all pertinent health data and history as it
applies to each individual patient.

Saying this,

the

researcher identified three common extraneous variables
that affect PCNPs clinical decision-making skills daily
that may have influenced the results of this study.
PCNPs work under protocols for practice in their
individualized work settings that reduce the ability of
the PCNPs to have completely independent decision making
authority over medications and treatment interventions
p rescribed to patients for the treatment of illness.

These

protocols are written by health care organizations to
simplify and clarify the treatment process for PCNPs to
efficiently treat illness in a cost-effective manner while
avoiding legal pitfalls.

They are approved and mandated by

a health care organization's administration to produce
this desired effect.

Due to these restrictions on

independent clinical decision making, many PCNPs
habitually treat varying illness by way of protocol.
m a y have affected the responses of some PCNPs who

This
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responded to Cagle's JNC VI Guidelines Compliance Survey.
It can be assumed that some of the PCNPs who completed and
returned the CJGC Survey work in settings that impose
treatment protocols and may have influenced these PCNPs to
respond habitually by protocol rather than treating each
case scenario independently with consideration of all
treatment options available to an PCNP.
The influence of pharmaceutical sales representatives
and preceptor physicians also play a part in the way a
PCNP treats hypertensive patients daily.

Pharmaceutical

sales representatives are constantly providing convincing
data from studies they have conducted on the efficacy of
their anti-hypertensive medicine and promote those
medications under patent heavily.

This generally means

that they are out to influence PCNPs to prescribe newer
agents without longstanding clinical trials rather than
the promotion of older agents with many clinical trials
that back their efficacy.
Physicians have preferences that affect PCNPs
prescribing as they are respected for their medical
knowledge and experience in the treatment of hypertension,
especially if the PCNP is relatively inexperienced as a
clinician and prescribes many of the same medicines as
their preceptor to prevent confusion and conflict with the
patients they treat together.

Siegel and Lopez argued that
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many physicians are prescribing newer agents,
calcium channel blockers and ACE inhibitors,

such as
as first-line

agents in hypertension treatment rather than the use of
b e t a -blockers and diuretics which have more long-term
clinical trial support for their effectiveness

(1997).

This pattern of prescriptive practice was seen by the
PCNPs who answered the CJGC Survey as well,

with ACE

inhibitors and calcium channel blockers being prescribed
more frequently than beta-blockers and diuretics for a
stage one essential hypertensive patient

(Case #1) when

the decision to treat the patient pharmaceutically was
chosen.

The importance of this finding by the research

data cannot be overlooked as it suggests that PCNPs are
looking to referred knowledge instead of clinical research
as a guide for practice which in the end threatens the
professional ability of the PCNP to be an independent
practitioner in the treatment of illness and places them
in the role of a physician extender,

which is not the role

of the PCNP.
Lastly,

patient compliance affects how PCNPs treat

hypertensive patients.

Every clinician knows that there is

never a perfect treatment regimen,

and patient preferences

and health beliefs affect outcomes of therapy. Many times
clinicians change their prescription practice and
treatment regimens due to multiple failures with a
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treatment recommendation to produce a desired health
change with their patients.

This may have been the case in

this study as many PCNPs did not treat an essential stage
1 hypertensive patient

(Case #1) with lifestyle

modifications for a period of 6 m o n t h s , which was a
recommendation of the JNC VI guidelines for such patients.
However,

an PCNP feels about the success of lifestyle

modification factors to lower blood pressure levels,

it

should be instituted because unneeded anti-hypertensive
therapy has side effects and cost that could be avoided.
Patients who are started on hypertensive medicines
generally also remain on them for life.
It was ironic that many PCNPs in the study initiated
treatment of a Stage 1 hypertensive patient with newer,
more expensive agents rather than a cheaper diuretic such
as hydrochlorothiazide,

but many PCNPs would not order and

echocardiogram or ECG in the diagnostic labs section of
the case studies for the assumed purpose of not placing
excessive cost on the patient.

One echocardiogram or EKG

to warrant the need for a newer more expensive agent is
cheaper in the long-run than placing a patient with
Medicare or Medicaid on an unneeded,
anti-hypertensive agent.

expensive,

newer,

Proper assessment of patients'

cardiovascular status is important as well due to the fact
that some patients with an MI would benefit from a beta-
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blocker as a person with congestive heart failure would
benefit from an ACE inhibitor and a diuretic agent or
combination.

Based upon the findings in this study,

PCNPs

still need improvement in the area of cost consideration
when contemplating the most efficient treatment for a
patient.
The current study found that,

although more PCNPs

were partially or compliant with the JNC VI guidelines
used in the CJGC Survey, many were noncompliant,

and the

largest number of PCNPs having only partial compliance.
NPs can use the results of this study to remind them of
the importance of following competent,

sound prescriptive

practice daily to support their ability to treat illness
as a primary care provider.
Upon analysis of the data and significant findings,
the researcher was cognizant of King's Theory of Goal
Attainment as a means of interpreting the data.

The

researcher found that the theory was appropriate to
analyze the results as it dealt with patient treatment by
PCNPs to meet a goal of appropriate blood pressure
measurements through education and pertinent treatment
strategies.
According to King's Theory of Goal Attainment,

a

nurse is a person with special health care knowledge and
skills that can communicate this knowledge to patients
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through interactions to mutually set goals to achieve a
state of health

(King,

1995).

The nurse uses specialized

knowledge of treatment regimens to help patients chose
interventions that will lead to the patient's desired
health goals.

The patient shares his health beliefs and

feelings about various treatment options after weighing
the benefits of each intervention and perceived outcome.
This exchange of information,
transaction,

as described by King as a

is essential to reach mutual goals which

produce satisfaction when obtained

(King,

1995).

PCNPs are

nurses with specialized knowledge to counsel and treat
patients with health disturbances such as hypertension.
PCNPs must be informed of the most recent scientific
knowledge that supports the use if various different anti
hypertensive regimens and their benefit to the patient,

as

well as competent in the prescribing of treatment regimens
that will provide the most benefit to the patient.
Health care providers practice in the information
generation where patients are researching the
effectiveness of their providers'

treatment

recommendations with the recommendations of experts in
diverse specialties of medicine and will more than likely
increase in the future.

PCNPs who do not stay up-to-date

with the recommendations of expert committees,
JNC VI,

such as the

take the risk of losing trust and the professional
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respect of their patients and colleagues. Although the JNC
VI guidelines are only recommendations,

they are regarded

by most health care professionals as the golden standard
for hypertension management and should be employed and
utilized as much as possible.
of extenuating circumstance,

There will always be cases
but this does not mean that

we should "throw the baby out with the bath water." The
JNC VI guidelines are sound principles for hypertension
treatment and provide legal protection to NPs if utilized
in their treatment regimens.

If PCNPs fail to share the

knowledge of these guidelines with patients,

specialized

knowledge concerning a health condition is not shared,
transactions are threatened,

and goals may be unobtained.

Limitations
There were potential limitations to the
generalization of the results.

The cost incurred by the

mailing and reproduction of the CJGC Survey and post card
questions limited the researcher to send out only 200 CJGC
Surveys and postcards which only yielded 37 PCNPs for the
study.

Due to the high cost of copies and postage,

the JNC

VI awareness question on the postcard was sent with the
second mailing of the CJGC Survey and could have created
insight,

therefore biases,

into the purpose of the study.

However,

the surveys that were returned with the postcards
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did not have higher scores than those surveys returned
without the JNC VI awareness question included.
Another limitation to the study was the lack of
biographical data that could have assessed for extraneous
variables that could alter the results of the study.

The

biographical data sheet did not assess for bias that may
have been caused by PCNPs working under strict
hypertension management protocols,

which was mentioned

earlier as a possible cause for noncompliant responses.
Also,

it would have been helpful to have a self-report on

how highly PCNPs believed their prescriptive practice
habits were affected by preceptor preference or
pharmaceutical sales information to rule this out as a
possible cause for noncompliance.

Significance to Nursing
Many NPs are currently fighting for the ability to
prescribe controlled substances to their patients.

The

analysis of the data concerning prescriptive practice that
was in compliance with the JNC VI guidelines found that
more PCNPs

(n = 23) were partially compliant or compliant

in the CJGC Survey than those PCNPs

(n = 13) who were not

compliant.

The majority of these PCNPs were only partially

compliant,

and there were only three guidelines used for

scoring of this compliance. Anti-hypertensive medications
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can have serious consequences if not prescribed
competently.

Hypotension,

rebound tachycardia,

heart block

progression,

bradycardia,

and dizziness are all possible

side effects or adverse effects of anti-hypertensive
medications if prescribed carelessly.

Controlled

substances also can have serious side effects and adverse
effects when prescribed incompetently,
compromise,

overdose,

addiction,

such as respiratory

and an increased

susceptibility to accidents and falls. The examination of
NPs'

prescription of drugs with possible adverse

consequences,

such as anti-hypertensives,

will be examined

in the future to assess the NP's ability to prescribe
drugs with possible adverse sequela competently and
provide competent monitoring of their patients on such
medications.
The results of this study should remind NP of the
importance of adequately prescribing all medications by
respected guidelines of various medical organizations to
prevent a lack of trust by patients in the treatment of
illness and to avoid legal and legislative pitfalls
related to prescriptive practice.

Conclusions
The results of this study implicate that PCNPs are
not functioning at a level of compliance in hypertension
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treatment consistent with the JNC VI guidelines.

This

evidenced noncompliance by PCNPs gives support to the need
for further,

different dissemination techniques of the JNC

guidelines for hypertension management in the future.
These findings are supported by the study of Goldberg and
colleagues,

who found that intensive academic detailing

programs and continuous quality improvement teams were
unsuccessful in producing an overall higher degree of
compliance to the JNC guidelines in health care providers
in clinical settings

(1998). The researcher found that

King's Theory of Goal Attainment was appropriate to
interpret the findings theoretically as it dealt with the
role of the nurse/PCNP as a person with specialized
knowledge in health care that must be shared and utilized
effectively during patient interactions for goals to be
set and obtained.

Recommendations
After extensive review of recent and past literature
related to the compliance of health care providers with
JNC hypertension management guidelines and the results of
this study,

the researcher makes the following

recommendations to improve the knowledge of hypertension
management related to JNC guidelines compliance in the
future :
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1. Dissemination of future guidelines should
incorporate case studies into the education process along
with current scientific research to justify the importance
of evidenced-based medicine in p r a c t i c e . This approach
would be most beneficial in the education programs of
health care professionals,
programs,

such as medical schools and NP

so that students have no preconceived or

influenced opinion on hypertension treatment,

but may be

successful in the form of continuing education seminars.
This approach also protects providers from feeling
threatened by outside influences and would allow open
discussion to help the health care provider gain valuable
information on the reliability of the JNC guidelines in
practice.
2. Replication of the study with a larger sample over
a larger geographical area.

This will help support or

refute the results of this study and provide an analysis
of data from which better generalizations can be made.
3. Conduction of research in the future of PCNPs'
prescriptive practice and treatment regimens of other
health care problems.

Further outcomes-based research will

point out areas of needed improvement in education and
practice,

as well as support the role of the PCNP in the

treatment of illness.

R EF ER EN CE S
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C agle's JNC VI Guidelines
Compliance Survey

The following case studies were designed to assess the
primary care nurse practitioners' management strategies
related to hypertension. The information you provide is
very important for recommendations in treatment of this
"silent killer" and appreciated very much. Following the
case studies, three categories of interventions will need
to be completed: pharmacologic interventions, n o n 
pharma co logic interventions, and diagnostic tests. The
pharmacologic and non-pharmacologic interventions will
need to be handwritten (please be as detailed as
p o s s i b l e ) . The diagnostic test portion can be checked for
each test that you would order in each situation.
Thank you for your time and participation in this study.
Please fill in personal information before starting as it
is crucial to how your responses will be analyzed in the
study.
Personal Data
What is your practice site?
O a. Hospital clinic
O b . Free clinic
O c . Health Department
ÜJ d. Private practice
Years of experience as a nurse practitioner:_______________
Your nurse practitioner specialty:
C3 a. Family nurse practitioner
O b . Adult nurse practitioner
Type of educational program attended:
O a. Certificate
O b . Master's
Average number of patients with hypertension you see a
day:__________________
CASE STUDIES START ON NEXT PAGE.
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Case #1
Mr. R., a 36 yr. old Caucasian male, who is slightly
overweight, presented to the clinic 2 weeks ago for an
insurance physical. He had an elevated B/P of 160/78, Body Mass
Index (BMI) of 2 8 , (BMI 25-29 is Overweight) and no other
abnormal findings. He had no previous history of hypertension.
His B/P was checked again one week later and was 156/80. Mr. R.
came in today with a B/P reading of 154/88. He was hospitalized
for a DVT at the age of 32 yrs. Mr. R. works as a contractor
for a local real estate firm and states he is "under stress
lately" due to the number of projects he is undertaking. Mr. R
confirms use of oral tobacco products, one can a week, and poor
diet due to being "on the run." Father has HTN. Grandfather on
mother's side died at the age of 58 yrs of MI. KNDA. No Hx of
surgeries or chronic illness. How would you treat this p t .?
PHARMACOLOGIC INTERVENTIONS :

NON-PHARMACOLOGIC INTERVENTIONS:

DIAGNOSTIC TESTS/LAB:
Urinalysis:___________________
CBC:___________
Fasting glucose:_____________
Lipid Profile:___________
TSH
E c h o c a r d i o g r a p h y :____________
24-hour urinary protein/creatinine clearance:__________________
E lectrolytes: ____________________
EKG:_________________________
Other. Please specify and give rationale:
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Case #2 :
A 52 y r . old Hispanic female with a Hx of COPD and GERD
presented to your clinic yesterday for her annual GYN exam, B/P
was 178/80, HR 80. Pt. was informed to return to clinic
tomorrow to recheck B/P. On return visit pt. C/0 of H/A with
B/P OF 198/74, HR 78. Pt. took B/P last night at home while
resting 168/78. P t . is on Medicaid. Her granddaughter lives
with her, and she helps raise three small grandchildren. NKDA,
immunizations are up-to-date. No surgeries. She was Dx with
atypical chest pain 3 yrs. ago. A stress test was done then
and was "normal." She also had an ECHO and EKG and pt said
that MD said that "left side of my heart is slightly enlarged."
She was Dx with GERD 3 yrs ago and takes Prilosec 20 mg QD. She
has had no chest pain since then. B/P has been treated for the
past 6 yrs by taking HCTZ 25 mg QD. She denies SOB at rest but
has periods of SOB with exertion and no chest pain since she
started Prilosec 3 years ago. She has no history of vision
problems or changes in vision. No tobacco or alcohol use. How
would you treat this pt?
PHARMACOLOGIC INTERVENTIONS :

NON-PHARMACOLOGIC INTERVENTIONS :

DIAGNOSTIC TESTS/LAB:
CBC:___________
U r i nalysis:___________________
Fasting glucose:_____________
Lipid Profile:___________
TSH:
E c h o c a r d i o g r a p h y :____________
24-hour urinary protein/creatinine clearance:___________________
Electrolytes:____________________
EKG:_________________________
Other. Please specify and give rationale:
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Case #3 :
Mr. G. a 45 yr. old African American male with a Hx of Type 1
DM and HTN, presents to the clinic on a Monday with c/o
weakness, and polyuria. He states his B/P medication is
"messing up his love life." B/P is 174/92 mmHg. He smokes one
pack of cigarettes daily, and drinks a 6 pack of beer on Friday
and Saturday weekly. His father died of a stroke at the age of
60 yrs. His mother is alive but has a Hx of chronic renal
failure, HTN, and Type 1 DM. He is currently taking Prinivil 10
mg BID but stopped 3 days ago due to the side-effects. The
patient has worked in construction for 20 years and has medical
insurance and a medicine card to cover prescriptions. Mr. G.
is on NPH insulin 40 units in a.m. and 20 units PM.
Pt states
FSBS is "up and down." How would you treat this pt?
PHARMACOLOGIC INTERVENTIONS :

NON-PHARMACOLOGIC INTERVENTIONS :

DIAOfOSTIC TESTS/LAB:
CBC:___________
Urinalysis:___________________
Fasting glucose:_____________
Lipid Profile:___________
TSH
E c h o c a r d i o g r a p h y :____________
24-hour urinary protein/creatinine clearance:__________________
Electrolytes:____________________
EKG:_________________________
Other. Please specify and give rationale:
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Vice President
for Academic Affairs
VH:wr
CO.

Mr. Jim D avidson
Dr. M ary Pat Curtis

Where Excellence is a Tradition

APPENDIX C
LETTER TO PARTICIPANTS

103

104

407 Aquarius Drive SW
Hartselle, AL 35437
(256) 773-2165
E-mail: Gerrgfnp0AOL.com
Static777 0 A O L .COM

Dear Prospective Participant:
I am writing this letter to gather participants for my
graduate research project on hypertension at the
Mississippi University for Women. The study is focused on
assessing family nurse practitioners' hypertension
management strategies to ascertain how this "silent
killer" is approached from both a nursing/caring modality
and the medical/curing modality in practice. The results
will be examined using King's Goal Attainment Theory and
will be disseminated back to participants, at their
discretion, following the completion of the study. An
attached questionnaire using vignettes is included with
instructions. This questionnaire will assess the family
nurse practitioner in hypertension management practice in
three areas: pharmacological, non-pharmacological, and
diagnostic tests ordered.
All information gathered from
the study will be kept confidential and used only for the
purpose of this study.
If you consent to participate, please fill out the
questionnaire and return it in the pre-addressed, stamped
envelope which has been provided. Please do not include
your name or address on the envelope to ensure
confidentiality. Your informed consent to participate in
the study will be implied with the return of the
questionnaire. You will be able to withdraw from the study
at any time, although any data already provided cannot be
removed from the study due to its anonymous nature.
Thank you for your time and consideration. If you have any
questions concerning the study, please contact me by
telephone, mail, or E-mail.
Sincerely,

Gregory N. Cagle,
MUW FNP Student

RN

APPENDIX D
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407 Aquarius Drive SW
Hartselle, AL 35437
(256) 773-2165
E-mail: Gerrgfnp0AOL.com
Static7770AOL.COM
Dear Prospective Participant:
If you have already sent back the vignettes I sent as part of
my research study, thank you for your participation. This
research, as I explained in my previous letter, is part of my
graduate program requirements at the Mississippi University for
Women. Data you provided are greatly appreciated. Data should
be analyzed soon along with the results. If you would like a
copy of the results. E-mail me at the address above, and I will
gladly send you the results of the study. For those who have
not been able to send the vignettes back, I am writing you to
remind you of the research study on hypertension that I am
conducting as part of my graduate program at Mississippi
University for Women. I am writing again to each prospective
participant to ask for their participation in this study. If
you think you can help, please send the questionnaire back by
the end of the month. I have enclosed another questionnaire and
a self-addressed, stamped envelope. Here is a brief description
of the study again to help with your decision.
The study is focused on assessing primary care nurse
practitioners' hypertension management strategies to ascertain
how this "silent killer" is approached from both a
nursing/caring modality and the medical/curing modality in
practice. The results will be examined using King's Goal
Attainment Theory and will
be disseminated to participants, at
their discretion, following the completion of the study.
All information gathered from the study will be kept
confidential and used only
for the purpose of this study.
Please do not include your
name or address on the envelope to
ensure confidentiality. Your consent to participate in the
study will be implied with the return of the questionnaire. You
will be able to withdraw from the study at any time, although
any data already provided cannot be removed from the study due
to its anonymous nature. I have one more request as part of the
study. I am asking one qualitative question in the study to
help explain the results obtained from the vignettes provided
to each PCNP included in the study. The question is a postcard
included with this letter and can be returned with the
questionnaire or by itself in the self-addressed, stamped
envelope provided. Your help with this part of the study will
also be greatly appreciated as it is an essential part of the
study for its completion. Once again, thank you for your time

107

and help in this study. I thank you for your time and
consideration. If you have any questions concerning the study,
please contact me by phone, mail, or E-mail.
Sincerely,

Gregory N. Cagle, RN
MUW FNP Student
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Please answer and return the following research
question:
Ar e you aware of the current national guidelines
(The Sixth Report of The Joint National
Committee on the Prediction, Detection,
Evaluation, and Treatment of High Blood
Pressure) for hypertension management?
Yes :
No:

0
0

(Fill in oval with black ink pen,

please)

